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 Amphotericin B is a drug of choice for severe and/or deep-seated ocular fungal infections 
(OFI). An ophthalmic marketed amphotericin B formulation is currently not available; parenteral 
marketed preparations (FungizoneTM and AmBisome®) are prescribed (off-label) to treat OFI 
(keratitis and endophthalmitis). Current amphotericin B off-label therapy to treat OFI requires 
frequent topical administration (every hour) due to the poor permeation and precorneal retention 
associated with it. Therefore, a need arises to formulate an ophthalmic preparation with multidose 
compatibility, enhanced precorneal retention, and reduced frequency of dosing, whilst, 
maintaining ocular tissue concentrations comparable/superior to the marketed preparations.  
The Chapter I work focuses on formulating and stabilizing amphotericin B-loaded nanostructured 
lipid carriers (AmB-NLC) by PEGylating using optimum PEG molecular weight and optimizing 
it for ocular drug delivery. A 4-week stability (physical and chemical), in vitro transcorneal 
permeability, in vitro antifungal efficacy and cytotoxicity, and in vivo ocular distribution following 
topical administration in rabbits for optimized formulations was evaluated. This is first attempt to 
formulate and optimize (design of experiment approach) PEG-NLC-AmB for ocular drug delivery 
with: an enhanced drug load, an organic solvent-free process, and using a high-pressure 
homogenizer. 
The Chapter II focuses on formulation of an optimized and robust amphotericin B ocular 
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formulation with prolonged precorneal residence and ocular tissue concentration at par or superior 
to the marketed preparations. Additionally, demonstrating stability of amphotericin B formulations 
in presence of preservative in comparison to marketed preparation, making it an ideal choice of 
formulation for multi-dosing. As mentioned earlier, we optimized PEGylated nanostructured lipid 
carriers (PEG-NLC-AmB) for ocular delivery of amphotericin B. The formulations could be 
autoclaved with at least one-month stability and in vivo ocular biodistribution was statistically 
insignificantly different compared to AmBisome®. To accomplish the aim, strategies such as 
mucoadhesion and/or viscosity enhancement were investigated.  In this regard, PEG-NLC-AmB 
entrapped in ion triggered hydrogels using gellan gum (mucoadhesive) and chitosan 
(mucoadhesive and permeation enhancer) coated PEG-NLC-AmB were formulated and 
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INTRODUCTION AND SPECIFIC AIMS 
Introduction to ocular drug delivery 
Epidemiology of ocular diseases 
Ocular drug delivery has remained a challenging task for pharmaceutical scientists. This coupled 
with the aging population and manifestation of other age-related diseases, explains why the 
National Eye Institute (NEI) has predicted a significant rise in clinical cases involving diseases 
affecting the ocular segments, across various age and ethnic groups (3). This review focuses on 
the rising use of noninvasive nanotechnology to improve the therapeutic outcomes in diseases 
affecting the anterior segment of the eye. The frequently encountered sight-threatening anterior 
segment ocular diseases are cataract, glaucoma, keratitis, ocular hypertension, and uveitis (4-7). 
According to the NEI and the World Health Organization (WHO), cataract is one of the major 
causes of blindness, accounting for 51 % of the blindness worldwide (3, 8-10). 
Topical administration, a localized noninvasive technique, is the most preferred route of dosing 
for anterior segment ocular diseases. The topical route, however, is associated with low ocular 
bioavailability (less than 5% of the administered dose) because of various physiological and 
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mechanical barriers (7). Conventional topical ophthalmic formulations include eye drops 
(solutions, suspensions) and ointments. Some emulsion formulations are also currently in the 
market (Restasis®, Cationorm®). Limited retention on the ocular surface and the need for the drug 
candidate to possess ideal physicochemical characteristics, to facilitate efficient penetration 
through the complex ocular structures, however, limits the efficiency of these dosage forms (11). 
Solutions are rapidly drained from the conjunctival cul de sac allowing very little time for the drug 
to partition into the ocular tissues. Moreover, the instilled drop size must be in the range of 25-50 
µL which does not allow for the development of a high concentration gradient across the ocular 
tissues and demands good solubility characteristics, especially at the pH of the tear fluids.  
To improve the efficacy of the topical ophthalmic solutions or suspensions, high viscosity 
(thixotropic or shear-thinning) solutions and hydrogels, have been developed to increase retention 
on the ocular surface (12). Moreover, in contrast to solutions, suspension formulations are better 
retained on the ocular surface because of the deposition of the drug particles in the conjunctival 
cul de sac. Suspensions are also the primary choice for compounds with poor aqueous solubility 
(in relation to the target dose). Compared to solutions and suspensions, ointments are not 
commonly used for conditions affecting the eye because of the oily components that affect vision 
for some time following application. In all cases, drainage through the nasolacrimal duct and 
systemic absorption, and consequent side-effects must be carefully monitored.  
The conventional formulation approaches discussed above can only increase the retention time on 
the ocular surface and does not improve trans-membrane penetration (in the absence of penetration 
enhancing formulation components). The complex ultrastructure of the cornea, enzymes, efflux 
proteins and the lymphatic and vascular systems, severely limits penetration of the therapeutic 
agent across the ocular tissues. Moreover, the ocular tissues are very sensitive; thus, the use of 
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permeation enhancers is limited in ophthalmic formulations (13, 14). Therefore, there is a pressing 
need for advanced ophthalmic formulations to circumvent the challenges associated with topical 
ocular drug delivery.  
Prior to looking at the potential formulation strategies, a brief discussion with respect to the 
diffusion pathways and the diffusional barriers encountered in topical administration is presented.  
 Routes of permeation following topical application 
Topically administered drugs can penetrate the deeper ocular tissues primarily through two routes 
(Figure 1). Transcorneal permeation – commonly referred to as the corneal pathway - is the 
predominant diffusional route from the ocular surface into the deeper ocular tissues, especially for 
access to the anterior segment tissues (15). However, for efficient transcorneal penetration, the 
physicochemical characteristics of the drug must be favorable and a delicate balance between 
hydrophilic and lipophilic characteristics is needed. Hydrophilic compounds appear to favor the 
non-corneal pathway, which involves permeation across the conjunctiva and sclera (conjunctival-
scleral pathway) into the deeper tissues of the eye since the conjunctival epithelium is leakier than 
the corneal epithelium. The conjunctival-scleral pathway is especially attractive for targeting the 
posterior segment tissues. The conjunctival and choroidal vasculature and lymphatics, however, 





Figure 1: Fate of API post-ocular instillation (reproduced from Therapeutic Delivery. 
(2018) 9(2), with permission of Future Science Group).  
Barriers to Topical Ophthalmic Drug Delivery 
Topically administered therapeutic agents, targeting the inner ocular tissues, encounter static, 
dynamic and metabolic barriers that limit ocular bioavailability. These barriers can be classified 
as precorneal, corneal, and the blood-ocular barriers (18, 19).  
Diffusional Barriers 
Precorneal Barriers 
The precorneal barrier affects both corneal and non-corneal pathways. Tear drainage forms a major 
precorneal barrier component (20-22). The conjunctival cul de sac can accommodate 
approximately 7-10 µL fluid; thus, a significant portion of the topically administered eyedrop, 35-
50 µL, is lost (23). Precorneal drainage not only causes the removal of the instilled formulation 
(drop/solution) but also reduces the corneal contact time for the formulation (24, 25). Patton, 1977, 
reported an inverse correlation between instillation volume and bioavailability (26-28). Also, the 
increased tear flow can lead to faster precorneal elimination and decreased efficacy. Osmolarity 
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and pH of the formulation are two important parameters that can trigger tear fluid generation (29). 
Additionally, tear fluid consists of proteins, to which the drug can bind, reducing the free drug 
concentration in the tear fluid (29).  Moreover, the multi-layered tear film, with its hydrophilic and 
hydrophobic components (30), also presents a diffusion challenge by itself. 
Diffusional Barriers in the Corneal Pathway 
Corneal Barrier: Cornea is a multi-layered barrier limiting drug penetration into the aqueous 
humor through the corneal pathway (17). It has layers with alternative lipophilic and hydrophilic 
characteristics; the epithelium (contains 5-6 layers of epithelial cells) and endothelium are 
lipophilic in nature, whereas, stroma is hydrophilic in nature. Hence, the pharmaceutical active 
should have optimum hydrophilicity/lipophilicity, and other physicochemical characteristics such 
as molecular weight, polar surface area, hydrogen bond donors and acceptors, for it to permeate 
efficiently across the cornea. Additionally, the corneal epithelial cells express tight junctions that 
restrict transcorneal paracellular diffusion, underlining the importance of the physicochemical 
characteristics and concentration gradients that govern transcellular, transcorneal diffusion. Efflux 
transporters, such as P-glycoprotein (P-gp) and multidrug-resistant proteins (MRPs), expressed on 
the corneal epithelium (31) present additional barriers to transcorneal diffusion of their substrates 
(19, 32-35).  Unlike the epithelial cells, corneal endothelium is leaky in nature, presenting little 
restriction to the movement of macromolecules between the stroma and aqueous humor (36). Thus, 
the corneal epithelium acts as the major barrier to transcorneal diffusion. 
Diffusional Barriers in the conjunctival – scleral (non-corneal) pathway 
Drug diffusion into the ocular tissue through the conjunctival-scleral pathway is also challenged. 
Although slightly leakier than the cornea (37), the conjunctival epithelium expresses efflux pumps 
that limits trans-conjunctival diffusion of its substrates. Since the conjunctiva is highly 
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vascularized, unlike the cornea which is avascular, a significant fraction of the drug molecules 
penetrating across the conjunctival epithelium is lost into the systemic circulation. Moreover, tear 
dilutes the topically administered drop and the blinking action spreads the diluted formulation over 
the ocular surface, further decreasing the trans-conjunctival concentration gradient. Thus, 
formulations that settle in the conjunctival sac, and is not easily dispersed across the ocular surface, 
may utilize the conjunctival-scleral pathway more efficiently. Some recent publications using 
topical films/inserts seem to utilize this route of entry into the deeper ocular tissues from the 
surface (38).  
Drug penetrating across the conjunctiva will reach the sclera from where it can reach the retina. 
The sclera is a poorly vascularized tissue comprising of collagen and mucopolysaccharides (39). 
Scleral permeability is significantly higher than that of the cornea; however, considering that very 
little of the topically administered agent reaches the episcleral region, the concentration gradient 
across the sclera will be low. Some portion of the drug can also migrate laterally across the sclera, 
which will further decrease the trans-scleral concentration gradient. As a result, following topical 
instillation trans-scleral flux can be low, even though trans-scleral permeability may be greater 
than transcorneal permeability. Other factors affecting the scleral permeability include molecular 
radius, physicochemical properties and the surface charge of the active moiety (40-44).  
The above discussion on the various barriers restricting ocular bioavailability of therapeutic agents 
following topical application is summarized in Table 1.  
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Table 1: Physiological challenges to ocular drug delivery (reproduced from Therapeutic 
Delivery. (2018) 9(2), with permission of Future Science Group). 




 Reduced pre-corneal residence time. 
 Frequent dosing required; leading to a reduced patient 
compliance. 
 Naso-lacrimal drainage leads to drug loss. 
 Systemic toxicity. 




 Reduce trans-corneal flux. 
 Poor drug solubility and permeability. 
 Drug storage instability leading to reduced efficacy 
and increased cost. 




 Damage to the ocular tissues (retinal necrosis, loss of 
retinal ganglion cells, vitreal inflammation, corneal 
edema, neovascularization, and inflammation) and 
occurrence of systemic toxicities (hepatoxicity and 






Metabolism in the ocular tissues  
Enzymes (glutathione and related enzymes) form the defense system against foreign chemicals 
and oxidative stress, to protect the eyes. Glutathione and glucose-6-phosphate dehydrogenase is 
found in lens, cornea, and retina (81). Metabolizing enzymes, such as oxidoreductases, 
hydrolases, present in the eye can metabolize the administered drug and thus affect the response 
intensity and duration (82). Various enzymes capable of metabolizing therapeutics agents present 
in the anterior segment ocular tissues is listed in the Table 2. 
Elimination Pathways 
The faction of the topically administered agent that reaches the aqueous humor faces additional 
elimination mechanisms, in the form of aqueous humor outflow, that limits exposure to the iris-
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ciliary bodies and lens. Aqueous humor turnover leads to loss of the drug through the Canal of 
Schlemm and trabecular meshwork and into the systemic circulation through the lymphatic 
circulation (83, 84). Diffusion into the microvasculature, present in the various parts of the eye, is 
another pathway via which the actives enter the systemic circulation (83, 85). Small lipophilic 
molecules are rapidly eliminated in comparison to large hydrophilic molecules ascribed to their 
ability to cross blood-aqueous barrier (BAB) and enter the systemic circulation (86). 
Table 2: Various metabolizing enzymes expressed in anterior segment ocular tissues 




Drug metabolizing enzymes References 
Cornea CYP-1A/2B/2C/3A/4B1, NADPH reductases, ketone 
reductases, esterases, arylamine acetyltransferase, 
Glutathione S-Transferase. Aldehyde oxidase. 




Aldehyde oxidase, Glutathione S-transferase, Esterase, 
ketone reductase, CYP-1A/1B1/2B/2C/3A/4B1/39A1. 
(81, 87, 88) 
Lens NaDC3, CYP2B, CYP2C, ketone Reductase (87-89) 




Challenges in polyene-based pharmacotherapy of ocular fungal 
infections 
Since the past decade there has been a steady rise in the incidences of ocular fungal 
infections such as keratitis, endophthalmitis, blepharitis, and conjunctivitis which affect nearly one 
million population in the United States, annually (90, 91). Of these, the incidences for fungal 
keratitis were the highest with an estimated 930,000 visits to doctor's office and outpatient clinics 
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and about 58,000 emergency department visits with about 76.5% of keratitis visits requiring drug 
prescriptions (91). Episodes of keratitis and other ocular fungal infections costed an estimated 
$175 million in direct health care expenditures, that included $58 million for Medicare patients 
and $12 million for Medicaid patients annually in the United States, according to an analysis 
reported by Collier et al in Morbidity and Mortality Weekly Report for Centers for Disease Control 
and Prevention (91).  
This increase in ocular fungal infections has been majorly attributed to the increase in the 
population of the immunocompromised patients, rapid emergence of resistance and cross-
resistance of the fungal species to antifungal agents, and the development of fungal infections due 
to more than a single fungal species (92). There are more than 105 different variants of fungi, 
encompassing 56 genera, that are known to cause ocular fungal infections such as keratitis, 
endophthalmitis, blepharitis, and conjunctivitis (93).   
The polyene and azole antifungals have been the mainstay in the pharmacotherapy of invasive 
systemic fungal infections due to their broad antifungal spectrum and potent biological activity 
(94, 95). The polyene class comprising of amphotericin B, nystatin, and natamycin have been 
widely used in therapy owing to their antifungal activity against Candida spp., Aspergillus spp., 
Fusarium spp., Scedosporium spp., and Zygomycetes class of fungi which are the common 
causative species for fungal infections (96, 97). The polyene antifungals also report few cases of 
emergence of resistance and cross-resistance and the use of lipid-based polyene formulations 
(especially amphotericin B) have provided alternatives with greater safety, tolerability, and lower 
toxicity profiles (98, 99). Azoles, like the polyenes, exhibit a broad spectrum of activity by eliciting 
both fungistatic and fungicidal activity. Azoles show biological activity against C. albicans and 
non-C. albicans spp., Fusarium spp., Aspergillus spp., and the Zygomycetes (100, 101). 
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Fluconazole is considered to be more cost effective, safe, and tolerable antifungal agent with low 
toxicity profile, whereas the other two clinically important azoles, itraconazole and voriconazole, 
even though possess a broad spectrum of potent antifungal activity, elicit toxic and adverse side-
effects (102).   
These polyene and azole antifungal agents have been used as the front-line therapeutic agents in 
invasive fungal systemic infections, onychomycosis, ophthalmic fungal infections, fungal 
dermatitis, and meningitis (103-107). However, their use in the ocular fungal therapy has been a 
challenge due to the unique ocular anatomy and their physicochemical properties. This is evident 
from the fact that, only natamycin has been available commercially for treatment of ophthalmic 
fungal infections, and the other antifungals are used off-label (95).  
The ocular fungal infections, like the other fungal infections, are on steady surge that necessitate 
the introduction of other polyene and azole antifungal drugs as commercial dosage forms that are 
potent and make a safe, tolerable, and cost-effective therapy.  
Chemistry, mechanism of action, and antifungal activity of the polyene antifungals  
Chemistry 
Polyenes are characterized by the presence of multiple conjugated double bonds (Figure 
2: [i (A)] and [ii(A)]) in a hydroxylated chromophore. Based on the number of the conjugated 
double bonds, amphotericin B and natamycin, are classified as heptaene and tetraene polyene 
antifungal drugs (108). The conjugated double bond lactone chromophore is known to possess an 
all-trans conformation and is essential for the antifungal activity and stability of amphotericin B 
and natamycin (109, 110). The conjugated double bonds impart lipophilicity and the hydroxylation 
on the chromophore imparts hydrophilicity to the two polyene antifungals. The chromophores of 
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both the polyene antifungal drugs (amphotericin B and natamycin) are also characterized by the 
attachment of a mycosamine (basic) moiety (Figure 2: [i(B)] and [ii(B)]) via an ether linkage and 
carboxylic (acidic) group (Figure 2: [i(C)] and [ii(C)]). These groups impart an 
amphoteric/amphipathic character to both the polyenes. The amino group in the mycosamine 
moiety exhibits a Ka of about 8.6 whereas the pKa value for the carboxyl group is reported to be 
around 4–4.5; rendering amphotericin B and natamycin as zwitterionic species with an isoelectric 
point at a pH range of approximately 5-7 (108, 111-113). The mycosamine and the carboxyl 
terminals impart a polar character (contribute to the relative insolubility in organic solvents), 
whereas the opposite unsaturated terminal imparts a non-polar character (contributes to the 
aqueous insolubility) to amphotericin B and natamycin (108, 113).  
Mechanism of action 
Fungi are eukaryotic organisms that contain sterols as the essential lipid components which are 
responsible for mediating their cellular and physiological functions. Most of these sterols are 
Figure 2: (i) Amphotericin B, (ii) Natamycin; [(A): Conjugated multiple bonds, (B): 
Mycosamine moiety, (C): Carboxylic group] (reproduced from Journal of Ocular 




similar to those found in humans; hence, a unique and specific fungal target (that is absent in 
human host) is essential for the effectiveness of an antifungal agent (114). Ergosterol, a sterol that 
is specifically present in the fungal species and absent in the human hosts, is one of the most 
common targets for an antifungal drug to elicit its activity (114, 115). Disruption of the ergosterol 
biosynthesis to deprive the fungal species of ergosterol (an essential structural and signaling sterol) 
constitutes the predominant mechanism of action of most of the polyene and azole antifungal 
agents (116, 117).  
Ergosterol is an essential fungal sterol that is responsible for maintaining the membrane fluidity 
and integrity and relaying the cellular signals in fungal cells (118). Polyene antifungal drugs are 
known to exhibit antifungal activity by binding to ergosterol and inhibiting its cellular functions 
with (amphotericin B) or without (natamycin) permeabilizing the fungal membrane (115, 119). 
Amphotericin B and natamycin are known to bind to ergosterol and inhibit its cellular activity 
leading to a fungicidal action (115, 120, 121). The binding of polyene antifungals to ergosterol 
results in inhibiting the ergosterol-dependent membrane fusion and fission processes, endocytosis, 
and plasma protein complexes leading to the death of the fungal species (122-128). Additionally, 
amphotericin B-ergosterol binding also results in the formation of aqueous pores leading to a 
permeabilization of the fungal cell membrane that causes the efflux of potassium and other cellular 
components eliciting antifungal activity (129, 130). The binding of amphotericin B to ergosterol 
is considered to be a predominant mode of action of amphotericin B in comparison to the 
permeabilizing effect that has been considered as a secondary mode of action (130, 131).   
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Figure 3 illustrates the mechanism of action of polyene antifungal drugs in fungal cells. 
Antifungal activity of Polyene antifungals and its comparison with Azoles  
Polyene antifungal drugs – amphotericin B and natamycin possess a broad spectrum of antifungal 
activity against filamentous and yeast-like fungi (natamycin exhibits weak to moderate action 
against the yeast-like fungal forms) (107, 119, 132). Table 3 elaborates on the antifungal activity 
Figure 3: Mechanism of action of polyene antifungal drugs in fungal cells (reproduced 
from Journal of Ocular Pharmacology and Therapeutics (2019) 35(1), with permission of 
Mary Ann Liebert Inc. Publishers). 
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of the two polyene drugs against various fungal species with the minimum inhibitory concentration 
(MIC) corresponding to each species.  
Table 3: Antifungal activity of amphotericin B and natamycin with their MIC against 
various clinically relevant fungal species (reproduced from Journal of Ocular 
Pharmacology and Therapeutics (2019) 35(1), with permission of Mary Ann Liebert Inc. 
Publishers). 
Species/strains Polyene drugs (MIC: µg/mL) Reference 
Amphotericin B Natamycin 
Candida 0.25-2 1-2 (130, 133-136) 
Aspergillus 1-4 5-40 (137-139) 
Fusarium 1->4 4-8 (137, 138, 140) 
Penicillium 1 1-3 (122, 141) 
Paecilomyces 0.25->16 2-6 (141) 
Rhizopus 0.5-2 2-6 (138, 142) 








0.25-4 1-25 (119, 122, 143-
146) 
 
Amongst the polyene class of antifungal drugs, amphotericin B shows the most potent activity 
with low MIC values (< 4 µg/mL) for all the clinically relevant fungal species (with a few 
exceptions from Paecilomyces species) that are responsible for the fungal infections in humans 
(Table 3). However, in comparison to amphotericin B, natamycin shows less potent activity with 
a broad MIC range for the fungal species (Table 3).  
Azole class of antifungals, like the polyene group, are broad spectrum antifungal agents. However, 
due to the presence of a variety of azole antifungals belonging to different generations; the class 
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shows variability in antifungal activity and potency against a variety of fungal species that are 
known to cause invasive and superficial fungal infections. Table 4 enlists the fungal species and 
MIC of the various azole drugs against them.  
Table 4: Antifungal activity of azoles with their MIC against various clinically relevant 
fungal species (reproduced from Journal of Ocular Pharmacology and Therapeutics (2019) 
35(1), with permission of Mary Ann Liebert Inc. Publishers). 
Species/ 
strains 
Azole drugs (MIC: µg/mL) Reference 
FLU ITR KET MICO VOR POS 
Candida 0.5-32 0.03-4 0.03-
>32 
0.02-8 0.03-4 ≤1 (147-149) 
Aspergillus >64 0.5-2.0 0.06-8 1.5-3.5 0.5-2.0 0.25-
0.5 
(150-153) 
Fusarium >64 32 0.1-50 0.07-40 0.5-8 0.25-16 (150, 154, 
155) 
Rhizopus >64 0.03-8 1-16 1->4 2->8 1-8 (150, 156) 
Cunninghamella >64 0.125-
2 














0.03–1 0.01-1 (150, 158, 
159) 
FLU: fluconazole; ITR: itraconazole; KET: ketoconazole; MICO: miconazole; VOR: 
voriconazole; POS: posaconazole 
 
Posaconazole and voriconazole, belonging to the most recent and newer generation of azoles, 
exhibit the highest potency and activity (in vitro, in vivo, and clinical studies) in comparison to all 
the earlier generation azole antifungals. Accordingly, posaconazole and voriconazole, have 




The polyene and azole class of antifungals exhibit susceptibility towards the emergence of fungal 
resistance like the antibacterial agents. The degree of susceptibility, however, differs between the 
two classes, with azole antifungals having greater predisposition to the development of fungal 
resistance than the polyene class of antifungals (115). Additionally, the mechanism of resistance 
in fungal species against the different classes of antifungal drugs also differs (152).  
The occurrence of resistance against polyene antifungals is less prevalent than the azole 
antifungals; however, resistance towards amphotericin B is observed in fungal species such as C. 
lusitaniae, C. glabrata, C. guilliermondii, A. terreus, and T. beigelii and against natamycin in A. 
parasiticus, A. flavus, and C. parapsilosis (115, 119, 160). An increase in the biosynthesis and 
accumulation of other sterols, as a replacement for ergosterol, with a concomitant reduction in 
biosynthesis of ergosterol (due to a modified and mutated ERG3 gene that causes a reduction in 
ergosterol synthesis) in fungal cell membranes has been implicated as one of the major modes for 
the development of polyene resistance (161). This has led to the emergence of resistant fungal 
species with low ergosterol content for the binding of polyene drugs to elicit their antifungal 
activity. Apart from these, replacement, reorientation, and/or masking of some or all the polyene-
binding sterols (ergosterol, cholesterol, or stigmasterol) with sterols having less affinity for 
polyenes (hindering their binding) has also been credited as one of the major factors in the 
emergence of resistance (108). The former reason coupled with decreased a susceptibility to 
oxidative damage due to an enhanced catalase activity has been attributed to the development of 
resistance against amphotericin B, whereas, the latter reason has been primarily associated with 
the emergence of fungal species having an innate resistance against natamycin (119, 160, 162). 
In comparison to the polyenes, resistance to azoles has been known to occur via multiple 
mechanisms. One of the major underlying mechanism has been the overexpression of active efflux 
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pumps due to the upregulation of the CDR (Confluence dependent resistance) and MDR (Multi 
drug resistance) genes that has led to a decreased concentration of the azole antifungal drugs within 
the fungal cells (due to their efflux) contributing to the emergence of resistance (163, 164). 
Mutations in the ERG11 gene that encodes the target enzyme (lanosterol C14α-demethylase) 
results in the alteration in the structure and chemistry of the enzyme that leads to a hindrance in 
the efficient binding of the azole drugs to the enzyme that causes the emergence of resistance 
against them (160). In some cases, just like the polyene antifungals, mutation of ERG3 genes 
leading to the inhibition of ergosterol biosynthesis and increase in the biosynthesis and 
accumulation of other sterols in the fungi has also been implicated as a predominant mode of 
development of resistance against azole drugs (165). Apart from these, upregulation of the ERG11 
gene responsible for the coding of target enzyme also occurs, leading to an increase in the target 
enzyme concentration in the fungal cells, thereby providing resistance against the azole drugs 
(166). Figure 4 provides an overview of the mechanism of resistance against polyene and azole 
antifungals that occurs in fungal cells.  
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Challenges to the ocular delivery of polyene and azole antifungals 
Anatomical and physiological limitations 
Topical route is the most preferred route for the administration of drugs in treating the ophthalmic 
infections and diseases. However, in treating the ocular fungal infections, the severity and 
localization of the fungal infection in ocular tissues dictates the route of drug administration (167). 
For example, most of the fungal infections of the anterior chamber are treated by administering 
the drugs topically, whereas in case of endophthalmitis or deep-seated mycoses, parenteral or 
intraocular injections are routinely employed (167).  
Figure 4: Schematic representation of the development of resistance against polyene and 
azole antifungals manifested in fungal species (reproduced from Journal of Ocular 




Targeting of antifungal drugs, especially polyene and azole antifungals, to the different infected 
ocular sites is still one of the formidable challenges associated with antifungal pharmacotherapy 
(168). This has been primarily attributed to the complex anatomy of the eye and the 
physicochemical properties of the various classes of antifungal drugs.  
Anatomical and physiological barriers pose significant challenges to the topically administered 
formulations of polyene and azole antifungals (76, 169). The anatomical barriers comprise of the 
different layers of cornea, sclera, retina, and blood-retinal and blood-aqueous barriers whereas, 
ocular blood flow, lymphatic clearance, tear dilution, and ocular enzymes and transporters 
constitute the physiological barriers (170-172). These barriers collectively affect the ocular 
pharmacokinetics of all the ocularly administered drug (173). The cornea, iris-ciliary, and sclera 
act as barriers to the permeation of the drug when administered topically for various drugs such as 
amphotericin B, natamycin, miconazole, ketoconazole, and fluconazole (76, 168, 174). Blood-
aqueous barrier (BAB) and blood-retinal barrier (BRB) collectively form the blood-ocular barriers 
for the entry of drugs into the posterior chamber (168). BAB is composed of the endothelial tight 
junctions present in the iris and ciliary epithelium. BAB inhibits the movement of drugs such as 
amphotericin B, natamycin, and ketoconazole into the posterior ocular milieu due to its tight 
cellular integrity (175-177). In case of severe inflammation or infection such as fungal 
endophthalmitis, BAB gets disrupted facilitating the passage of solutes or drugs through it. Hence, 
in cases of severe fungal keratitis topically administered amphotericin B, fluconazole, 
itraconazole, and ketoconazole are found to easily penetrate the cornea and BAB (attributed to the 
loss of corneal integrity due to inflammation and keratitis) to enter the posterior chamber in 
contrast to the insignificant or no penetration of the drug in healthy individuals (167, 178, 179). 
BRB hinders the penetration of solutes and drugs from entering the retina and posterior chamber 
 
35 
from the blood (76, 167, 179). The retinal blood vessels and chorioepithelial cells form the inner 
BRB and retinal capillary endothelial cells and retinal pigment cells form the outer BRB. Retina 
acts as a vascular barrier to the permeation of drugs having molecular weight greater than 76 kDa, 
including the polyene and azole category antifungals, into the posterior chamber in case of 
parenteral administration of the drug (70). The anatomical barriers are significantly responsible 
for altering the drug penetration, bioavailability, and intraocular concentration (175, 180-182).  
The physiological barriers, also known as the dynamic barriers, act as hindrances to the ocular 
delivery of drugs. Topical application of polyene and azole drugs as a solution or a suspension 
leads to considerable losses due to the naso-lachrymal drainage (183-185). Additionally, the tear 
film is also responsible in reducing the topical residence time of the antifungal drugs as the tear 
film is replaced every 2-20 mins in human eyes (175, 186). To overcome these losses, higher drug 
concentrations are instilled which lead to adverse side-effects and toxicity at the ocular site, 
particularly in the case of amphotericin B and ketoconazole, thereby establishing a threshold for 
the maximum concentration of the antifungal that can be instilled into the eye (168). The tear film 
is also responsible for affecting the ocular drug pharmacokinetics by binding to the drugs. The tear 
film, composed of mucin, salts, enzymes, and proteins, has been shown to bind anti-infective drug 
classes such as antifungals and antibacterials, there-by posing as a challenge to their ocular 
therapeutic delivery (83, 175, 187-189). Additionally, the lipoidal tear film also poses as a barrier 
for the diffusion of hydrophilic drugs (such as fluconazole and natamycin) via the cornea, thereby 
reducing the drug penetration into the inner ocular tissues (83, 175, 190).  
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Figure 5 provides a brief overview on the anatomical and physiological ocular barriers that 
compromise the ocular pharmacokinetics of the drugs. 
Physicochemical limitations 
The physicochemical properties of drugs affect their ability penetrate the ocular barriers to reach 
their site of activity in the ocular milieu. One of the major challenges associated with the antifungal 
agents is their large molecular weight and poor aqueous solubility (168, 169). The ocular delivery 
of amphotericin B is challenging due to its high molecular weight and low aqueous solubility 
which hinders its penetration across the cornea and blood-retinal barrier, which severely limits its 
ocular bioavailability (168). The reduced bioavailability of itraconazole and natamycin due to poor 
corneal penetration has also been attributed to their high molecular weights (167). Additionally, 
binding of itraconazole to the proteins in the tear-lipoidal film and high hydrophobicity have 
Figure 5: Brief overview on the anatomical and physiological ocular barriers that 
compromise the ocular pharmacokinetics of the drugs (reproduced from Journal of Ocular 




contributed to its poor corneal penetration upon topical administration (167, 168). Ketoconazole 
and miconazole have also exhibited poor penetration across the cornea and blood-retinal barrier 
due to their high molecular weights, hydrophobic characters and tendencies to undergo protein 
binding (168). Voriconazole, even though has a broad and potent spectrum of activity in ocular 
fungal infections, its ocular use is limited due to the visual disturbances that have been exclusively 
associated as a side-effect with this azole drug (168). Thus, high molecular weight, high 
hydrophobic character, and poor aqueous solubility have been the major physicochemical 
challenges to the ocular delivery of polyene and azole antifungal drugs. 
Selective potent antifungal activity 
Selective potent action of polyene and azole antifungals is one of the major challenges associated 
with their monotherapy. This is observed from the MIC values for these drugs that have been 
elaborated in Table 1 and 2. The potent selectivity in their antifungal activity has been abundantly 
evidenced and discussed in literature. Amongst the polyene class of antifungals, natamycin is 
known to have a potent activity against filamentous fungi such as Aspergillus and Fusarium but 
only a weak to moderate activity against the yeast-like fungi (76, 95, 119). This has led to the use 
of natamycin as a front-line therapy drug in treating superficial ocular fungal keratitis caused by 
Fusarium and Aspergillus species (119). In treating fungal keratitis complicated by both 
filamentous and yeast-like fungal species, multiple antifungal drug regimen is initiated using 
natamycin concomitantly with miconazole, itraconazole, ketoconazole, or fluconazole (191). 
Similarly, amphotericin B has shown variability in its activity against the filamentous fungal 
species, especially Fusarium species, and shown a potent activity against the Candida species 
(179). This has led to its frequent use as an off-label antifungal agent in treating the cases of severe 
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Candida keratitis but not in cases of Fusarium keratitis in which natamycin is preferred (93). 
Fluconazole also is known to have weak to moderate action against the filamentous fungi but 
excellent action against Candida species making it an ideal agent in the treatment of deep-seated 
Candida keratitis and not a preferred candidate in the therapy of filamentous fungi caused keratitis 
(179, 192). Itraconazole and miconazole show variable activity against the filamentous fungal 
species with a potent activity against Aspergillus species and a weak activity against Fusarium 
species making it suitable candidate in treating deep-seated Aspergillus infection but not in the 
case of Fusarium infections (179).  
Ocular and systemic drug toxicity 
The polyene and azole antifungals are known to elicit ocular and systemic toxicities which 
manifests as one the challenges associated with their therapy. In a toxicity evaluation by Foster et 
al., the ocular toxicity of the clinically used polyene and azole antifungals (amphotericin B, 
flucytosine, miconazole, and ketoconazole) was studied on debrided rabbit cornea, in vivo, upon 
topical application of these antifungals as 1% solutions or suspensions (193). The evaluations were 
based on rate of closure of the debrided epithelial corneal wounds, quality of regenerating 
epithelium, stromal edema and haze, and iritis (visual and microscopic evaluations). It was found 
that amphotericin B severely retarded the rate of debrided corneal closure and manifested dramatic 
pathologic changes (evaluated on the bases of scores for quality of regenerating epithelium, 
stromal edema and haze, and iritis) which worsened each day with the continuation of therapy. 
However, ketoconazole, flucytosine, and miconazole produced histologically undetectable 
changes; indicating their relative efficacy and safety in antifungal therapy involving corneal 
debridement (in diseases such as fungal keratitis and endophthalmitis). The ocular toxicity of 
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amphotericin B has also been corroborated by various studies, in which, it has shown to cause 
retinal toxicity, loss of retinal ganglion cells, vitreal inflammation, corneal edema, 
neovascularization, and inflammation, upon its prolonged and frequent use as intraocular 
injections (71-75). Similarly, itraconazole and voriconazole are known to cause retinal necrosis 
and visual disturbances upon their intraocular injections and oral use, respectively (77-79). 
Systemic side-effects/toxicities such as nephrotoxicity (amphotericin B), hepatotoxicity 
(ketoconazole and voriconazole), and gastrointestinal upsets (itraconazole) are also commonly 
encountered upon their oral and/or intravenous administration in ocular fungal infections (45, 70, 
76, 77). Hence, from the above-mentioned discussion it is evident that ocular and systemic 
toxicities manifest an important challenge in their ocular delivery.  
Emergence of resistance and cross-resistance 
Antifungal resistance has been one of the major challenges associated with the antifungal drug 
consortium; particularly with the azole antifungals (160). Clinical instances of primary and 
secondary resistances are observed for the different antifungal drugs (160). Polyene antifungals 
are generally associated with primary resistance, meaning, some of the fungal species are 
inherently and naturally resistant to them. Such a kind of primary or intrinsic resistance is observed 
against amphotericin B in C. lusitaniae, A. terreus, and T. beigelii and against natamycin in A. 
parasiticus, A. flavus, and C. parapsilosis (119, 150, 194, 195). Azoles in contrast to the polyene 
drugs exhibit both primary and secondary resistance (resistance due to a prolonged exposure of 
the fungal species to the azole antifungals) (107). For example, C. krusei is known to be resistant 
towards fluconazole and secondary resistance is emerging in C. albicans and C. glabrata against 
fluconazole at a rapid pace due to the continuous clinical use of fluconazole (107, 196). 
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Additionally, cross-resistance has also been one of the challenges plaguing the use of azole drugs. 
Widespread and continuous use of itraconazole and fluconazole has resulted in the development 
of resistant species against them and also against other antifungals (107, 115, 160). The emergence 
of resistance and cross-resistance against the newer azoles like voriconazole is emerging with 
reports of voriconazole resistant Fusarium keratitis and Aspergillus ocular fungal infections being 
reported. Use of posaconazole instead of voriconazole in the former case and surgical method in 
the latter, helped in overcoming the challenge of resistance associated with voriconazole (197, 
198). Currently, posaconazole is considered to be one of the most suitable therapies in cases of 
resistant fungal keratitis and other refractory ocular fungal infections (197-199).  
Lack of robust clinical in vitro susceptibility testing 
One of the challenges associated with antifungal agents, especially azole drugs, is the lack of 
clinical in vitro susceptibility testing that provides a robust in vivo correlation. This is owing to 
the fact that the in vitro susceptibility testing with fungal species is not yet standardized, and the 
results of in vitro tests do not always compare to the results obtained in vivo (107). The absence 
of the standardized tests for in vitro susceptibility testing in mycotic keratitis is attributed to 
small sample sizes, non-uniformity of MIC data due to the presence of various in vitro 
susceptibility testing methods and focus on one particular species (200). One such challenge has 
been observed in the evaluation of the most suitable polyene and/or azole antifungal in treating 
Fusarium keratitis due to the MIC variability for the different polyene/azole antifungals between 
and within the different Fusarium strains that cause the ocular keratitis (154).  Similar case has 
been frequently observed for fluconazole, which shows a weak in vitro activity against Candida 
and C. neoformans isolates but a potent in vivo activity against them (158). This has been 
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attributed to the lack of standardized in vitro susceptibility testing methods for the antifungal 
agents. Sensitive, specific, reliable, reproducible, and standardized in vitro susceptibility testing 
methods are warranted for the accurate and timely diagnosis of fungal infections, particularly 
fungal keratitis, to avoid treatment failures and relapses with the polyene and azole drug based 
ocular pharmacotherapy (154).  
Approaches at overcoming the challenges for the ocular delivery of polyene antifungal 
drugs 
Drug delivery and formulation approaches have been one of the most preferred options for 
overcoming the anatomical and physiological ocular barriers, physicochemical challenges, and 
ocular and systemic toxicities/side-effects associated with the polyene and azole drugs. One of the 
primary routes that has been undertaken to overcome the anatomical barrier associated reduced 
drug penetration is the improvement in the pre-corneal residence time of the formulation to 
improve the drug penetration by a prolonged contact upon topical application and/or by using 
intraocular injections (168).  
To improve the ocular bioavailability and safety of amphotericin B, both, formulation and 
alternative drug delivery approaches were utilized to overcome the anatomical and physiological 
barriers (45). Different lipoidal formulations (amphotericin B lipid complex (ABLC), liposomal 
amphotericin B (L-AMB), and amphotericin B deoxycholate (D-AMB)) of amphotericin B were 
developed and evaluated for their ocular penetration, biodistribution, and safety in rabbit eyes, in 
vivo, after intravenous administration. It was found that all the amphotericin B lipoidal 
formulations penetrated the blood-retinal barrier in the inflamed eyes and the concentration of 
amphotericin B following L-AMB administration was approximately 8 times more than ABLC 
and D-AMB formulations. So also, it was found that L-AMB reached higher concentrations and 
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was safer, in both, the aqueous and vitreous chambers, than the ABLC and D-AMB formulations 
upon intravenous administration. This study demonstrated the utility of liposomal amphotericin B 
formulations upon intravenous administration in deep-seated fungal infections and/or fungal 
inflammations, as an alternative to the topical administration of amphotericin B. In yet another 
study, amphotericin B lipid emulsion was found to penetrate the corneal barrier upon topical 
instillation and was shown to be safer than the marketed amphotericin B formulation (Fungizone®) 
upon multiple instillations (one instillation at every hour for 6 hours) in rabbits, in vivo (46). The 
improved bioavailability and safety associated with liposomal formulations of amphotericin B in 
comparison to marketed amphotericin B (Fungizone®) was also corroborated by Barza et al. and 
Tremblay et al., in in vivo studies carried out on rhesus monkeys and rabbits, respectively (47, 48). 
In two independent studies, positively charged amphotericin B loaded Eudragit® RL100 
nanoparticles and positively charged chitosan/lecithin nanoparticles exhibited greater corneal 
penetration due to an improvement in the pre-corneal residence time and bioavailability by 
providing mucoadhesion in rabbit eyes, in vivo (49-51). Apart from providing significantly higher 
corneal penetration to the marketed amphotericin B formulation (Fungizone®), the nanoparticles 
also exhibited sustained release and potent antifungal activity against Fusarium Solani, Candida 
albicans, and Aspergillus fumigatus, in vitro.  To overcome the aqueous solubility 
physicochemical challenges, Serrano et al. prepared γ-cyclodextrin complexed amphotericin B 
solution (67). The formulation was found to be significantly more stable (physical and chemical 
stability) with an improvement (approximately 35%) in its in vitro antifungal activity against 
Candida albicans compared to the marketed Fungizone® formulation.  
Nanoparticulate approaches have also been utilized to overcome the anatomical and physiological 
challenges that are associated with the ocular delivery of natamycin and to target the antifungal 
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drugs to overcome their ocular and systemic toxicities. In the study by Bhatta et al. and Chandasana 
et al., lecithin/chitosan nanoparticles encapsulating natamycin and poly-D-glucosamine (PDG) 
functionalized polycaprolactone (PCL) nanoparticles (PDG-PCL-NPs) encapsulating natamycin 
were developed with the aim of improving the ocular residence time and providing a sustained 
release of natamycin (52, 53). Upon in vitro evaluation, it was found that the natamycin release 
was sustained over seven and eight hours, respectively, for both the nanoparticulate carriers in 
comparison to the marketed formulation (natamycin suspension). In vivo evaluations revealed that 
the antifungal potency of the nanoparticles and the marketed natamycin suspension was 
statistically non-significant. The ocular pharmacokinetic studies demonstrated statistically higher 
concentration of natamycin from the nanoparticles in comparison to the marketed suspension 
(observed from a higher AUC0-∞ for nanoparticles than the suspension) and a lower clearance at 
the pre-corneal sites. The mucoadhesive property of the nanoparticles was attributed to be the 
reason for improved bioavailability and for overcoming the ocular anatomical challenges. and in 
vivo. Additionally, natamycin loaded niosomes delivered using an in-situ gel showed a safe 
(absence of any signs of ocular irritation and/or inflammation in rabbit eyes, in vivo) and sustained 
release of natamycin over 24 hours in comparison to the marketed natamycin suspension upon 
both in vitro and ex vivo evaluation (54). All these formulations exhibited significantly higher 
safety in comparison to the marketed natamycin suspension in rabbits, in vivo. Apart from these, 
several other approaches such as improving the aqueous solubility of natamycin by complexing 
them with cyclodextrins, formulating them in different lipid formulations are also being actively 
worked upon as potential ways to circumnavigate the physicochemical challenges associated with 
its ocular delivery (68, 119).  
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To overcome the challenges associated with the development of resistance and potential 
therapeutic relapse associated with monotherapy, usually, combination antifungal therapy is 
initiated (201). The data, however, remains scarce in this regard due to quick replacement and/or 
substitution of one antifungal drug with the other in cases of development of resistance and/or 
relapse (76). Generally, to overcome the relapse of Candida infections posaconazole and 
caspofungin combination therapy is initiated, whereas, posaconazole and voriconazole, and 
anidulafungin and posaconazole, combinations are frequent approaches for treating A. fumigatus 
infections effectively (202). Similarly, more effectiveness was observed against Fusarium species 
when amphotericin B was used in combination with terbinafine and itraconazole in comparison to 
its lone use, in vitro, indicating amphotericin B concomitant therapy with terbinafine and 
itraconazole could be more efficacious clinically (203). Itraconazole and micafungin combination, 
5-flucytosine and amphotericin B, and voriconazole and anidulafungin combination have also 
shown superior clinical activity and efficacy in comparison to itraconazole, 5-flucytosine, and 
voriconazole monotherapies in systemic fungal infections indicating that these combinations could 
also be utilized in ocular fungal infections (119, 204).   
Combination therapy is also a preferred choice to overcome the challenge of resistance associated 
with antifungal pharmacotherapy (76). Amphotericin B and fluconazole combination have shown 
efficacy in the treatment of keratomycosis and in reducing the clinical cases of relapse in 
comparison to the monotherapies with the antifungals (205).      
Table 5 summarizes the challenges that are associated with the ocular delivery of polyene and 
azole antifungals and also enlists the possible approaches/alternatives to overcome the challenges. 
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Table 5: Summary of the challenges and possible approaches at overcoming the challenges 
associated with the ocular delivery of polyene and azole antifungal drugs (reproduced from 
Journal of Ocular Pharmacology and Therapeutics (2019) 35(1), with permission of Mary 
Ann Liebert Inc. Publishers). 







 Frequent dosing 
leading to a 
reduced patient 
compliance. 
 Drug losses due to 
naso-lachrymal 
drainage. 
 Systemic toxicity. 
 Ocular toxicity. 
 Delivery of drugs using novel 
drug delivery systems such as 
nanoparticles, films, liposomes, 
mucoadhesive formulations, 
ocular implants, etc., for 
targeting of drugs to the ocular 
site. 
 Use of excipients such as 
chitosan, poloxamer, EDTA to 
improve the pre-corneal 
residence times and enhance the 
drug penetration. 
 To deliver the drugs as gels and 
viscous suspensions and 
emulsions to improve the pre-
corneal residence time and 







 Poor drug 
solubility. 
 Drug storage 
instability leading 
to reduced efficacy 
and increased cost. 
 Use of above-mentioned novel 
drug delivery systems for the 
delivery of polyene and azole 
antifungals.  
 Use of salt forms of drugs, their 
complexation with 
cyclodextrins, etc., to improve 
their aqueous solubility.  
 Encapsulation of drugs in 
surfactant and lipid core (in case 
of niosomal drug delivery) for 
improving its trans-corneal 
permeation and/or flux. 





 Damage to the 
ocular tissues 
(retinal necrosis, 
loss of retinal 
 Ocular targeting of drugs for 
treating of the ocular fungal 
infections using novel drug 


























 Efficacy of 
pharmacotherapy 
is reduced and 




 Combination therapy is initiated. 
 Newer generation of antifungals 
such as posaconazole, 
ravuconazole, echinocandins, 




 Limited activity of 
a drug against a 
given fungal 
species/strain.  





 Increase in severity 
of the infection 
over the time. 
 Combination therapy is initiated. 
 Newer generation of antifungals 
such as posaconazole, 
ravuconazole, echinocandins,  




The overall objective of this project is to develop an amphotericin B loaded formulation for ocular 
drug delivery and to treat severe ocular infections. For these purposes, formulation ought to have 
certain properties, such as sterility, compatible with preservative for multidose regimen, 
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enhanced permeation, prolonged precorneal retention to reduce frequency of dosing (to prevent 
adverse systemic effects and patient compliance), retain/enhance anti-fungal activity of pure 
drug, and safety. Keeping these desirable characteristics in mind, we aimed to fabricate 
nanostructured lipid carriers for amphotericin B. Amphotericin B is a potent polyene anti-fungal, 
a choice of drug for severe ocular fungal infections. The formulations were optimized and evaluated 
for its stability, autoclavability, and ex vivo/ in vivo to demonstrate feasibility of nanostructured lipid 
carriers for ocular drug delivery. These nanoparticles’ in vitro antifungal activity and cytotoxicity 
were evaluated. This project also highlights utility of PEGylation to stabilize drug loading in the 
nanoparticles. Various surface modifications, such as chitosan coated nanostructured lipid carriers 
and gel entrapped PEGylated nanoparticles, were also studied to deliver and prolong precorneal 
residence of amphotericin B. Additionally, effect of preservative (Benzalkonium chloride) was 
studied on amphotericin B formulation’s physical and chemical stability. To compare precorneal tear 
fluid kinetics, non-compartmental analysis was applied.  
Specific aims 
Develop nanostructured lipid carriers for ocular drug delivery of amphotericin B and study effect of 
PEGylation on the nanostructured lipid carriers. To fabricate, optimize, stabilize, and evaluate ocular 
biodistribution of amphotericin B loaded PEGylated nanostructured lipid carriers for ocular drug 
delivery. 
 Demonstrate stability enhancing effect of mPEG-DSPE and effect of PEG lengths on drug 
loading. 
 Optimize amphotericin B-loaded PEGylated nanostructured lipid carriers and study its effect 
on formulation characteristics using Design of Experiments approach. 
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 Effect of autoclave sterilization cycle on the formulation’s physico-chemical characteristics. 
 Demonstrate four-week stability of the optimized system. 
 Fabrication and characterization of gel entrapped chitosan coated- and PEGylated- 
amphotericin B loaded nanostructured lipid carriers. 
 Study effect of gel entrapped chitosan coated- and PEGylated- amphotericin B loaded 
nanostructured lipid carriers on precorneal retention and amphotericin B permeation.  
 Study effect of preservative (Benzalkonium chloride) on physical and chemical stability of 
amphotericin B formulations. 
 Evaluate ocular biodistribution of these nanostructured lipid carriers in New Zealand rabbits 






Optimization, Stabilization, And Characterization of Amphotericin B 
Loaded Nanostructured Lipid Carriers for Ocular Drug Delivery 
Introduction 
Ocular fungal infections, if not treated in time, lead to permanently impaired vision and can be 
life-threatening in certain cases, especially immunocompromised patients (206). Currently, 
natamycin ophthalmic suspension is the only approved and commercially available formulation 
that is used to treat infected superficial ocular tissues (Keratomycosis). Natamycin, however, is 
not very effective against Candida, which is the most common fungal species causing ocular 
fungal infection (207). Once treatment failure with natamycin is observed, physicians switch to 
other off-label topical antifungals or systemic therapy (208). Treatment of infections caused by 
deep-rooted fungi require potent antifungals, such as amphotericin B (AmB), fluconazole, and 
voriconazole (209), either alone or in combination (administered topically or systemically) (207). 
AmB is a potent polyene anti-mycotic and drug-of-choice to treat infections caused by invasive 
pathogenic fungi, such as Candida spp., Aspergillus fumigatus, Cryptococcus neoformans, and 
protozoan parasite Leishmania spp. (207, 210). The newer generation azole antifungals, such as 
fluconazole, voriconazole, and posaconazole, have similar potency and better ocular permeation 
in comparison with AmB but retain major disadvantages of the azole class of antifungals: 
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resistance and cross-resistance (207, 210-212).  
Despite the potency and clinical utility of AmB, there are various challenges in ocular delivery of 
AmB, which needs to be addressed to allow its transition into therapeutics. It is extremely 
lipophilic; practically insoluble in water, methanol, and ethanol; with a molecular weight of 924.1 
Daltons; and a log P of 0.8, making it challenging to formulate an effective dosage form. In 
addition to these challenges, ocular permeation of AmB and ocular barriers—such as tear turnover, 
the complex ultrastructure of the cornea, various metabolizing enzymes, and efflux transporters—
also manifests as formidable barriers (6, 213, 214).  
Currently, there is no approved ophthalmic AmB formulation in the market. Thus, in cases of 
severe fungal infection, the marketed preparations for intravenous administration (freeze-dried 
powders) reconstituted in sterile water or saline are used. However, the marketed preparations 
post-reconstitution needs to be used within a day, if stored at room temperature in a dark room, or 
1 week if stored at 4oC following reconstitution with sterile water for injection (as per the 
instruction from the manufacturer). Furthermore, AmB marketed formulations are incompatible 
with preservatives (bacteriostatic agents) and electrolytes (sodium chloride) making development 
of multi-dose formulations impractical with current formulation strategies (215).  
In recent years, nanoparticulate dosage forms have emerged as a promising ocular formulation 
platform for poorly water-soluble compounds due to enhanced retention on the ocular surface as 
well as better penetration into the ocular tissues. A few attempts have been made to fabricate AmB 
formulations for ocular drug delivery, such as Eudragit® nanoparticles, chitosan and lecithin-
based nanoparticles (216), micro-emulsion (217), cyclodextrin-poloxamer nanoparticles (218-
220). These reports have presented in vitro anti-fungal activity, drug release profiles, ocular 
irritation studies and pre-corneal residence kinetics. However, evaluation of stability, safety, and 
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biodistribution in animal models (proving suitability for ocular drug delivery) have been lacking 
in these studies. Furthermore, effect of sterilization on the nanoparticulate formulations and 
residual organic solvents are also lacking.  
Lipid nanoparticles enhances drug loading and permeation of the lipophilic molecules (221). 
Mucoadhesive, stable, and stealth nanoparticles are achieved with surface modifying agents, such 
as polyethylene glycol (PEG), chitosan, lipids with the amine functional group, etc. PEGylation 
renders the surface of the nanoparticles hydrophilic; It enhances ocular bioavailability by 
interacting with mucous and epithelium of the cornea (222-224).  It stabilizes nanoparticles (stearic 
stabilization) as well as drug in the nanoparticles by reducing contact with the surroundings 
(enzymes, oxidants, other degradation causing agents) (222, 225-227). PEGylation can either be 
attained by conjugation (mPEG-DSPE) or electrostatic interaction (PEG-SH) with the lipid (223, 
224, 227, 228). The major advantage of conjugated PEG is to prevent dissociation of the PEG over 
time in the aqueous environment (222).  
The current work focuses on formulating and stabilizing amphotericin B-loaded nanostructured 
lipid carriers (AmB-NLC) by PEGylating using optimum PEG molecular weightand optimizing it 
for ocular drug delivery. A 4-week stability (physical and chemical), in vitro transcorneal 
permeability, in vitro antifungal efficacy and cytotoxicity, and in vivo ocular distribution following 
topical administration in rabbits for optimized formulations was evaluated. So far, only a couple 
of reports on AmB lipid nanoparticles (1, 2) have been published; however, this would be the first 
attempt to formulate and optimize (design of experiment approach) PEG-NLC-AmB for ocular 
drug delivery with: an enhanced drug load, an organic solvent-free process, and using a high-
pressure homogenizer—which facilitates production scale-up. 
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Materials and methods 
 Materials 
AmB was purchased from Cayman Chemicals Pvt. Ltd. (Michigan, US). The solid lipids 
(CompritolTM 888 ATO, PrecirolTM ATO 5, GeleolTM, DynasanTM 114, DynasanTM 116, 
GelucireTM 43/01, GelucireTM 44/14, GelucireTM 50/13) and liquid lipids (LabrafilmTM, MaisineTM, 
and Capryol 90TM) were gift samples from Gattefossé (Weil and Rhein, Germany). DSPE-PEG-
2K-(N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine- mPEG-2000-DSPE) was obtained from Lipoid GmbH (Germany). All 
other molecular weight mPEG-DSPE were obtained from Creative PEGWorks® (Chapel Hill, NC, 
USA). Surfactants, olive oil, castor oil, oleic acid, and analytical grade solvents were procured 
from Fisher scientific (Massachusetts, US). Whole eyes of male albino New Zealand rabbits for 
the transcorneal study were procured from Pel-Freez® Biologicals (Rogers, AR, USA). 
 Lipid screening 
Lipid screening was performed to identify a solid and liquid lipid with highest AmB solubility 
and/ or dispersibility; without forming aggregates upon cooling. One gram of each lipid was 
weighed and heated to 75oC in scintillation vials. To these lipids, AmB was added in small 
accurately weighed portions with constant stirring. The mixture was cooled to room temperature 
and assessed for drug aggregation as well as homogeneity, with the naked eye and under the 
microscope. 
 PEG Screening 
Various molecular weight of PEG in DSPE-PEG (1K, 2K, 5K, 10K, 20K) were screened by 
forming PEG-NLC-AmB using these molecular weights (223). These formulations were compared 
for physical stability of the formulation (Table 6). 
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Table 6: Preliminary experiment with PEGylated and non-PEGylated NLCs. 
Ingredients Non-PEGylated NLC (%w/v) PEGylated NLC (%w/v) 
Lipid Phase 
PrecirolTM ATO 5 
Castor Oil 





























Fabrication of PEGylated and Non-PEGylated NLC  
AmB-NLC were prepared using the formula in Table 7. The lipid phase along with AmB was 
heated to 75oC and a coarse emulsion was formed by dropwise addition of the aqueous phase to 
the lipid phase under magnetic stirring at 2000 rpm. Further, the ULTRA-TURRAX® T 25 (IKA 
works INC., NC, USA) was used to homogenize the coarse emulsion into a fine emulsion at 16000 
rpm (temperature: 60o C). This fine emulsion was homogenized (temperature: 50o C) at 1500 bars 
for 5-15 mins in high-pressure homogenization (HPH) (Emulsiflex C5-Avestin, Canada). The 
amphotericin B loaded PEGylated nanostructured lipid carriers (PEG-NLC-AmB) were prepared 
by substituting Cremophor® EL with mPEG-DSPE (desired PEG molecular weight) in the lipid 
phase.  
Table 7: NLC and PEGylated NLC. 
Ingredients Non-PEGylated NLC (%w/v) PEGylated NLC (%w/v) 
Lipid Phase 
PrecirolTM ATO 5 
Castor Oil 






























*Mol. Wt of mPEG in mPEG DSPE (1K, 2K, 5K, 10K, and 20K) chosen as required. 
 
 
PEGylated NLC optimization 
A three-level response surface design (Box-Behnken Design) was used to optimize the PEGylated 
NLC for maximum drug loading, minimum particle size, and Polydispersity index, with a reduced 
number of trials without compromising on efficiency and accuracy (229). In this experiment, 3 
formulation (DSPE-PEG-2K, AmB, castor oil) and one process parameter (no. of cycles of HPH) 
were varied to study its effect on particle size, PDI, entrapment efficiency, and drug loading (Table 
8, Table 9). The experimental design was generated and analyzed using Design Expert® version 8 
(Stat-Ease, INC, MN, US). 
Table 8: Design factors. 
 Factors/Independent variables/Predictors 
Coded DSPE PEG 2000 Amphotericin B No of cycles Castor oil 
Level % (x1) % (x2) (x3) % (x4) 
Low (-1) 0.75 0.1 5 1 
Medium (0) 1.5 0.2 10 2 
High (1) 2.25 0.3 15 3 
 
Table 9: Box-Behnken design layout. 
 Factor 1 Factor 2 Factor 3 Factor 4 
Run A: DSPE PEG 2000 B: Amphotericin B C: No of cycles D: Castor oil 
 mg mg in HPH mg 
1 300 20 10 4 
2 150 20 20 4 
3 150 40 20 2 
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4 300 20 30 4 
5 300 20 20 6 
6 450 40 20 6 
7 300 40 10 6 
8 150 40 10 4 
9 450 60 20 4 
10 300 40 20 4 
11 300 60 10 4 
12 300 60 20 2 
13 300 40 30 2 
14 300 40 10 2 
15 300 40 30 6 
16 300 20 20 2 
17 150 60 20 4 
18 150 40 20 6 
19 300 60 30 4 
20 300 60 20 6 
21 150 40 30 4 
22 450 40 30 4 
23 450 20 20 4 
24 450 40 10 4 
25 450 40 20 2 
 
High-pressure liquid chromatography (HPLC) analysis 
AmB was quantified using a previously published HPLC method with some modifications (230). 
HPLC used was a Waters 717 plus auto-sampler coupled with a Waters 2487 Dual λ Absorbance 
UV detector, a Waters 600 controller pump, and an Agilent 3395 Integrator. A Phenomenex 
Luna® PFP (2) column with 5µ packing and dimensions 4.6 mm × 250 mm was used for the 
analysis. The mobile phase was 0.05 N sodium acetate and acetonitrile mixed with the ratio of 7:3. 
The retention time for AmB was 11.6 min, detected at the wavelength (λmax) of 407 nm. The 
standard curve of AmB, ranging from 0.1 µg/mL to 20 µg/mL, was prepared with a mixture 
containing equal proportions of dimethyl sulfoxide (DMSO) and methanol. The method was 
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validated for precision (inter- and intra-day), accuracy, linearity, limit of quantification, and limit 
of detection.  
 Bioanalytical Method for quantification of AmB 
For quantification of AmB in the in vivo samples, a Waters Xevo TQ-S triple quadrupole tandem 
mass spectrometer with an electrospray ionization source, equipped with the ACQUITY UPLC® 
I-Class System was used (Waters Corporation, Milford, MA, USA). Data acquisition was 
performed with Waters Xevo TQ-S quantitative analysis TargetLynx® software and data 
processing was executed with MassLynx® mass spectrometry software. Separation operations 
were accomplished using a C18 column (Acquity UPLC® BEH C18 100 mm×2.1 m, 1.7μm 
particle size). The mobile phase consisted of water (A), and acetonitrile (B) both containing 0.1 % 
formic acid at a flow rate of 1.0 mL/min with a gradient elution as follows: 0 min, 98 % A/2 % B 
held for 0.2 minutes and in next 2.3 min to 100% B. Each run was followed by a 1-minute wash 
with 100 % B and an equilibration period of 2 minutes with 98 % A/2 % B. The column and sample 
temperature were maintained at 50ºC and 10C, respectively. The effluent from the LC column 
was directed into the ESI probe. Mass spectrometer conditions were optimized to obtain maximal 
sensitivity. The following conditions were used for the electrospray ionization (ESI) source: source 
temperature 150°C, desolvation temperature 600°C, capillary voltage 3.0 kV, cone voltage 40 V, 
nebulizer pressure, 7 bar and nebulizer gas 1100 L·h−1 N2. Argon was used as the collision gas. 
The collision energies were optimized and ranged from 10 to 15 eV for individual analytes. 
Instrument control and data processing were performed by using MassLynx® software (version 
4.1, Waters, Milford, MA, USA). Mass spectra were acquired in positive mode and multiple 
reaction monitoring (MRM) mode. The multiple reaction monitoring (MRM) mode was applied 
to monitor the transitions of quantifier ion to qualifier ions (the precursor to fragment ions 
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transitions) of m/z 924.4  m/z 107.5, 743.2, 761.4 for AmB and m/z 666.2  m/z 467.2, 485.2, 
503.2 for natamycin. Natamycin was used as the internal standard. Confirmation of compounds 
was achieved through three fragment ions. 
AmB was quantified - by inverse prediction of concentration from the peak area obtained for LC-
MS/MS—using a calibration curve (coefficient of determination r2 ≥ 0.98) determined for ocular 
tissues, such as the cornea, Iris-Ciliary Bodies, Aqueous Humor, Vitreous Humor, and Sclera. The 
process and extraction efficiency were greater than 90% for all the tissues. 
 Physicochemical characterization of NLC 
Assay, drug loading, and entrapment efficiency 
The drug was extracted from NLC with a 50:50 solvent mixture of DMSO and methanol. For the 
total drug content, the formulation (10 µL) was diluted 100 times with the solvent mixture (990 
µL), stirred vigorously, and centrifuged at 13000 rpm. The drug in the supernatant was quantified 
using HPLC. Entrapment efficiency of the drug was calculated by determining the free 
unentrapped drug. The formulation was filtered through the Amicon® filters (pore size of 100,000 
Daltons) at 5000 rpm. The drug in the filtrate was quantified with HPLC. Percent entrapped drug 














  (2.2) 
Where, Wt = Total AmB content in the formulation  
 Wf = AmB in the aqueous phase 
 Wl = Total weight of the nanoparticles. 
 
58 
Particle size, PDI, and zeta potential 
Dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, USA) was used to measure 
mean hydrodynamic particle size (z-average), PDI, and zeta potential. The formulations were 
diluted 100 times prior to measurements. All the measurements were made at 25oC.  
Scanning transmission electron microscopy (STEM) 
A drop (20 µL) of the optimized PEG-NLC-AmB was placed on parafilm. A 200 mesh copper 
grids coated with a thin carbon film was exposed—film side down—to the drop of the PEG-NLC-
AmB. After 30 seconds, the grid was raised, and excess PEG-NLC-AmB was removed using a 
filter paper. Immediately, the grids were placed on a drop of ultra-pure water. Further, the grid was 
raised—excess water was removed—and placed on a drop of 1% uranyl acetate to stain the 
nanoparticles (231). After a minute, the grid was raised dried completely and examined under a 
Zeiss Auriga microscope (Carl Zeiss, New York) operating in STEM mode at 30kV.  
In vitro antifungal activity 
 Antifungal susceptibility assay was performed as per Clinical & Laboratory Standards Institute 
(CLSI) protocols (232-234). AmB formulations were tested against three pathogenic fungi: 
Candida albicans (ATCC 90028), AmB resistant Candida albicans (ATCC 200955) and 
Aspergillus fumigatus (ATCC 204305), following CLSI guidelines. Nanoparticle formulations 
were serially diluted using assay medium (RPMI 1640, pH 7.0). Diluted samples were transferred 
to 96 well assay plates (10 μL) in duplicate. Inocula was prepared by suspending growth from agar 
in 0.9% saline and diluted in RPMI 1640 (pH7.0, MOPS) medium after comparison to the 0.5 
McFarland standard to have a final inoculum of 1.0 x 104 CFU/ml for Candida and 2.7 X 104 
CFU/mL for Aspergillus in 190 μL of the medium.  The assay plates were measured at the OD530 
wavelengths prior to and after incubation at 35°C for 48h. MICs, defined as the lowest test 
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concentration that allows no visual growth, were calculated for all formulations. To determine 
MFCs, 4 μL aliquots of cells from each well was spotted on drug-free SD agar plates and was 
incubated for 24-48h.  MFC is defined as the lowest test concentration that allows no detectable 
growth on agar plate. All experiments were performed in triplicates.  
Cytotoxicity Assay 
The cytotoxicity of the selected formulations was determined against human retinal pigmented 
epithelium cells - ARPE-19 (ATCC CRL-2302).  The cells were seeded in 96-well plates at a 
density of 10,000 cells/well. After an incubation of 24 hrs, formulation samples at various dilutions 
were added and the cells were further incubated for 48 hrs. Cellular viability was determined by 
using a tetrazolium dye (WST-8), which is converted to a water-soluble formazan product in 
presence of 1- methoxy PMS by the activity of cellular dehydrogenases. The color of formazan 
product was measured by reading the absorbance at 450 nm. Percent decrease in cell viability of 
formulation treated cells was calculated in comparison to the vehicle treated cells. Doxorubicin 
and benzalkonium chloride were included as the positive controls for cytotoxicity towards the 
selected cell lines. 
 In vitro transcorneal permeability 
Freshly excised whole eye globe stored in Hank’s balanced salt solution (HBSS) solution on ice 
was shipped overnight from Pel-Freez® Biologicals. Upon receipt, corneas were separated and 
washed with phosphate buffer saline (PBS, pH 7.4) and mounted for transcorneal studies on 
modified Franz diffusion cells (PermeGear® Inc., Cranford, NJ) with a spherical joint (235-237). 
The water jacket around the cells maintained a constant temperature (34 ± 0.2°C, simulated 
average ocular surface temperature). The receptor chamber was filled with 2.5 % randomly 
methylated cyclodextrin mixed with Dulbecco’s phosphate-buffered saline (DPBS) and the donor 
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was filled (1 mL) with 0.3 % w/v AmB formulations—AmB-NLC and AmBisome® (control)—
diluted using sterile water for infection, respectively. PEGylated NLC and AmBisome® were 
evaluated for transcorneal permeation. The aliquots of 300 µl were drawn and replaced with the 
donor solution and aliquots were analyzed for AmB using HPLC. The weight of the corneas was 
recorded before and after the experiment to evaluate corneal hydration, indicating corneal 
integrity. Further, the corneas were homogenized; the drug was extracted from the cornea and 
analyzed using HPLC.  
 In vivo ocular bio-distribution studies 
In vivo, ocular biodistribution of AmB was studied in 8 male New Zealand albino rabbits (weighing 
around 2 - 2.5 kg), procured from Harlan Labs (Indianapolis, IN, USA). All animal studies 
conformed to the tenets of the Association for Research in Vision and Ophthalmology statement 
on the use of animals in ophthalmic vision and research and the University of Mississippi 
Institutional Animal Care and Use Committee approved protocols. Rabbits were anesthetized 
using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg), injected intramuscularly.  
The AmB formulations, PEG-NLC-AmB, and AmBisome® (marketed AmB liposomes), were 
evaluated in vivo in conscious rabbits (n=4). Six doses of each formulation were administered 
(50 μL each) 60 min apart. One-hour post-instillation of the final dose, the rabbits were euthanized 
with an overdose of pentobarbital injected through a marginal ear vein. The eyes were washed 
thoroughly with ice-cold phosphate-buffered saline and enucleated. All the ocular tissues were 
separated and homogenized; The drug was extracted from the tissues using an ice-cold solvent 
mixture (9:1- methanol: DMSO) and analyzed for AmB content according to the procedure 
described in Section 2.6. 
Fourier transform infrared (FTIR) spectroscopy and powder X-ray diffraction 
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The infrared spectra (IR) of AmB-NLC, blank PEGylated NLC and all its excipients were obtained 
using Cary 660 series FTIR (Agilent Technologies) and MIRacle ATR (attenuated total 
reflectance) systems. The ratios of AmB and lipids used in this set of studies were similar to the 
weight ratios in the PEG-NLC-AmB.  
A qualitative PXRD was done to examine the physical state of amphotericin B in PEG-NLC-AmB. 
The X-ray powder diffraction patterns of the samples were recorded with the Rigaku Ultima IV 
X-ray diffractometer using Ni-filtered, CuKα radiation generated at 40 kV, and a current intensity 
of 44 mA. The instrument was operated over a diffraction angle (2θ) ranging from 5° to 50°. 
Stability of the NLC 
Optimized PEG-NLC-AmB were autoclaved (AMSCO® Scientific Model SI-120) in the 
scintillation vials, at 121°C for 15 min under 15 psi pressure. The autoclaved samples were 
gradually cooled to room temperature and formulations were evaluated for its physicochemical 
characteristics (Section 2.7). The non-sterile formulations (stored at 4 and 25oC) were controls for 
the sterile formulations.  The optimized PEGylated NLC was evaluated for its stability upon 
storage for a duration of 8 weeks at 25°C/75% RH and 4°C. The physicochemical evaluations were 
performed as mentioned earlier in this chapter.  
Statistical analysis 
Analysis of variance (ANOVA) was used to analyze data from the experimental design. At p<0.05, 
the differences in data were considered statistically significant. The interaction, simple-effects, and 
plots for the experimental design were obtained using the R project for statistical computing 
version 3.4.4. 
Results and discussions 
Development of PEG-NLC-AmB 
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The objective of this study was to formulate and optimize PEG-NLC-AmB (Amphotericin B 
loaded PEGylated nanostructured lipid particles) for ocular drug delivery. Lipid screening is a 
crucial step to select the lipids with the highest drug solubility and/ or dispersibility. AmB had 
higher solubility at elevated temperature in PrecirolTM ATO 5 in comparison with the other lipids 
(Table 10). Castor oil was selected as the liquid lipid, due to its ability to best disperse/solubilize 
AmB in comparison with other liquid lipids (Table 10). 
Table 10: Lipid screening. 




Maisine - Precirol (+) 
Capryol - GMS - 
Olive Oil - Dynasan 114 - 
Sesame Oil - Dynasan 116 - 
Soy bean oil - Gelucire 43/01 - 
Captex 200 - Gelucire 44/14 - 
Captex 355 - Gelucire 50/13 - 
Oleic acid -   
Castor Oil +   
*+: Soluble/dispersed, (+): Drug aggregated upon cooling, -: Drug remain aggregated 
 
From DSPE-PEG screening experiment, it was observed that molecular weight of PEG in mPEG-
DSPE played a key role in entrapping AmB and preventing its leaching from NLC (Figure 6). 
Surprising results were observed; PEGylation (DSPE-PEG-2000-1.5% w/v) not only enhanced 
physical stability of the NLCs, but also enhanced amphotericin B loading and prevented its 
leaching over time (Figures 7,8,9, 10, and 11). In addition to DSPE-PEG-2K, other DSPE-PEGs 
of varying molecular weight (1K, 5K, 10K, 20K) were tested for their ability to enhance drug 
loading.  The formulations using DSPE-PEG-10K and DSPE-PEG-20K were physically unstable 
and lipid aggregates were observed. NLC with DSPE-PEG-5K had black residues at the bottom of 
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the vials, these indicated some type of chemical instability (either drug or lipid or DSPE-PEG-2K 
degradation).  
 
Figure 6:Precipitation of drug over the time: a)1-day, b) 8-days. Vials to the left: 




Figure 7: Visual observation of Amphotericin B loaded PEGylated NLC with various PEG 
mol. wt. from left to right: 1K, 2K, 5K, 10K, 20K. First row represents day 1 and second row 


































Figure 8: Effect of autoclave on Particle Size and its 8-day stability. 
 
Figure 9: Effect of autoclave on PDI and its 8-day stability. 
 


































































Figure 11: Effect of autoclave on assay (percent drug content) and its 8-day stability. 
We observed that amphotericin B is chemically stable on autoclaving but the NLCs in the colloidal 
dispersion were physically unstable (statistically significant increase in particle size and PDI) at 
amphotericin B loads of 0.05 % w/v and higher. This might be due to absence of bulky PEG corona 
surrounding NLC that protects and stabilizes them by steric hindrance (225). The drug precipitated 
out and formed a cake (not easily dispersed upon shaking) at the bottom. 
The formulations (colloidal dispersion) prepared with DSPE-PEG-1K was physically stable for 8 
days, both pre- and post- autoclave. There was a decrease in amphotericin B content (statistically 
significant).  Some precipitation was seen with the naked eyes (relatively more than 2K, but less 
than 5K) at the bottom of the vials but was redispersible. Note that a 7-14-day stability post 
reconstitution would be a significant advantage over what is currently available. Both pre- and 






























8 days. There was some precipitation seen at the bottom of the vials but was easily and completely 
redispersible. This precipitate might be larger lipid nanoparticles (PDI ~0.3-0.35). DSPE-PEG-
5K: There was statically significant increase in PDI post-autoclave, however the remaining 
formulation characteristics remained the same. DSPE-PEG-10K and DSPE-PEG-20K: There 
was significant drop in assay post-autoclave and the formulations were not physically stable. The 
post-autoclaved samples crystallized and froze at 4oC. The formulations,1K, 2K, 5K, were slightly 
orangish upon autoclaving. There was black residue seen in formulations which had DSPE-PEG 
(5K, 10K, and 20K). Over one-month there are large particles observed in formulations containing 
DSPE-PEG-10K and -20K (Table 11).  
Table 11: Visual inspection on day 1 and day 8 for amphotericin B loaded NLC (PEGylated and 
















































































































To further understand this effect, mPEG-2000-DSPE concentration was varied at 3 levels as a part 
of the design of experiments. The amount of castor oil, AmB, and number of HPH cycles were 
also varied in the experimental design to maximize entrapment and drug loading. 
Optimization of the PEGylated NLC 
The PEG-NLC-AmB was optimized using Box-Behnken design (Table 12). The formulation was 
optimized to study the effect of PEGylation (amount of mPEG-2000-DSPE) on drug loading, 
stability, and various physicochemical characteristics of the formulation. Several factors (based on 
preliminary trial) were noted, which causes variation in the formulation characteristics, to choose 
the factor relevant to our hypothesis. Surfactant type and concentration cause variation in particle 
size and PDI by moderating interfacial tension (238). Unless surfactant has an effect on the lipid 
phase, it does not cause increase in drug loading, however, it can lead to reduced entrapment 
efficiency by increasing solubility of the drug in the aqueous phase (micelles) (221, 239).  
Moreover, particle size, PDI, entrapment efficiency, and drug loading are affected by the type and 
concentration of solid and liquid lipid (240). The non-toxic concentration of the surfactants was 
used (241). The in vitro and in vivo histology was performed for current optimized formulations 
to evaluate the safety of PEG-NLC-AmB. Additionally, optimized formulation was evaluated for 
in vitro cytotoxicity and anti-fungal activity. 
Table 12: Model summaries. 
Parameters Entrapment efficiency (Y3) Drug Loading (Y4) 





X1 (DSPE-PEG) 5.62 0.085 -0.32 <0.0001* 
X2 (Amphotericin B) - - 1.64 <0.0001*  
X3 (No. of cycle of HPH) 7.98 0.018* - - 





X1X2 - - -0.53 <0.05 
X1X3 -11.84 0.039* - - 
X12 - - 0.5 0.005 
X42 - - 0.36 0.0323 
R2 0.41 - 0.94 - 
Adj. R2 0.33 - 0.91 - 
F value 4.88 (df=3,1) - 43.49 (df=6,1) - 
Model p-value 0.009* - < 0.0001* - 
                *p-value<0.05 
 
The two major challenges in formulating the PEG-NLC-AmB are: the drug solubility/ 
dispersibility in lipid and leaching out of the drug. mPEG-2000-DSPE or Cremophor® EL 
increased drug loading, however, Cremophor® EL failed to prevent drug leaching.  
 2 2 2 2
0 1 1 2 2 3 3 4 4 5 1 2 6 1 3 7 1 4 8 2 3 9 2 4 10 3 4 11 1 12 2 13 3 14 4x x x x x x x x x x x x x x x x x x xy x                             (2.3) 
Twenty-five formulations were prepared using the Box-Behnken design. Particle size, zeta 
potential, polydispersity index, entrapment efficiency, and drug loading were the responses (Table 
12). ANOVA was applied to fit the model and understand the effect of predictors on responses 
(equation 2.3). The significant model terms were selected by an automated stepwise procedure 
(Table 12). The linear, two-factor interaction and the quadratic models were compared using the 
goodness-of-fit, analysis of variance and adjusted r2 in Design Expert version 8 (2.3). The positive 
unstandardized coefficients (β) represent an increase in response variable with a unit increase in 
the factor considering all the other factor in the equation constant (2.3); The reverse applies to the 
negative coefficients—unless there exist an significant statistical interaction (242). A significant 
interaction (product of two factors) implies that the effect of a factor is moderated by other factor 
(243), which signifies that effect of a factor on response variable is different at different levels of 
moderator (another interacting factor). The intercept of the model is average response. The model 
was considered statistically significant, when the F-value is higher than Fcrictical (at p<0.05), which 
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validates existence of a linear relationship between the predictors and the response variable, 
however, adjusted r2 evince strength of this relationship (Table 12).  
Particle size, polydispersity index, and zeta potential 
The mean particle size for the experimental runs was 275 nm, the polydispersity index was 0.35, 
and zeta potential was -52.5 mV. The model for particle size, PDI, and zeta potential was not a 
good fit. Therefore, the effect of all the factors on variation in particle size, PDI, and zeta potential 
was statistically insignificant. The variation observed in these parameters might be due to a 
confounding factor, such as the temperature of the solution during homogenization or errors 
(instrumental and/ or manual). Therefore, the formulation is robust for particle size, PDI, and zeta 
potential at various levels of the factors (concentration of AmB, mPEG-2000-DSPE, and castor 
oil). The variations in data can further be reduced by stringent and uniform manufacturing 
conditions. There were few responses with higher particle size and PDI, therefore we need to 
perform more experiments with true replicates to understand these outliers.  
Entrapment efficiency 
1 3 1 3Entrapment Efficiency (%)   98.43 5.62* 7.98* -11.84* *x x x x     (2.4) 
The mean percent entrapment efficiency was 98.43 % (w/w). Amount of mPEG-2000-DSPE and 
no. of cycles of HPH are represented as x1 and x3 respectively in the equation. There exists a 
significant interaction (F (1,1) = 4.28, p-value-00395) between the amount of mPEG-2000-DSPE 
and no. of cycles of HPH. Therefore, the effect of mPEG-2000-DSPE on entrapment efficiency 
changes when no. of cycles of HPH changes. Increase in mPEG-2000-DSPE concentration 
increases entrapment efficiency when the formulation was homogenized for 10 HPH cycles, 
however, this effect is absent when the formulation was homogenized for 30 mins (Figure 12). 
This interesting effect of DSPE-PEG-2K may be due to interaction (physical and chemical) with 
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AmB. Additionally, nature of DSPE-PEG-2K interaction with AmB needs to be studied. No. of 
HPH cycles caused increased AmB loading, which may be due to increased particle-particles 




Figure 12: Contour plot and 3-D surface plot illustrating the interaction between 
amphotericin B and DSPE-PEG-2000. 
Drug loading 
2 2
1 2 21 1 2Drug Loading (%) 2.82- 0.32* 1.64* - 0.53* 0.5 0.36x x x x x x      (2.5) 
The mean drug loading was 2.82 % (w/w). Drug loading was significantly affected by the 
concentration of mPEG-2000-DSPE, AmB. From the experiments (Figure 13), we observed 
amount of AmB had a positive effect on the drug load. The effect of castor oil was not statistically 
significant on the drug loading. At 0.1% AmB, increase in mPEG-2000-DSPE lead to increase in 
drug loading, however, at 0.3 % (w/w), increase in mPEG-2000-DSPE lead to reduced drug 
loading. From the preliminary trials, it was also seen that mPEG-2000-DSPE is essential for 





Figure 13: 3-D surface plot and contour plot illustrating interaction between amphotericin B 
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The constraints (desired responses) were added in the Design Expert® version 8 to obtain 
optimized values of the predictors. The constraints were maximum entrapment efficiency and drug 
loading. The optimized independent variables are presented in Table 13 with the desirability of 
0.9. The particle size and PDI for the optimized formulation were found to be 218 ± 5 nm and 0.3 
± 0.02. The particle size of the PEG-NLC-AmB were confirmed by STEM imaging (Figure 14). 
The drug loading for the optimized PEG-NLC-AmB was found to be 4.6 ± 0.1 % (w/w) and the 
entrapment efficiency was found to be 92.7 ± 2.5 % (w/w).  
Table 13: Optimized value of the predictor variables. 
Variables Optimized value (%) 
DSPE-PEG-2K 0.75 
Amphotericin B 0.3 
Castor Oil 2 





Figure 14: STEM image of the optimized formulation.  
FTIR And PXRD analysis 
From the FTIR analysis, no conclusive results were obtained. The PEG-NLC-AmB, as well as a 
physical mixture containing AmB, lacked characteristic peaks of AmB, which can be attributed to 
insensitivity of the instrument to extremely low concentrations of AmB. However, powder X-ray 
diffraction—provides a unique fingerprint for crystalline substance—was performed to obtain 
decisive results. The unique peaks for AmB were 13.96, 15.1, 17.17, 18.26, however, none of these 
peaks were present in the PXRD spectra of PEG-NLC-AmB (Figure 15). Therefore, we can 




Figure 15: P-XRD spectra for blank NLC, amphotericin B NLC, and amphotericin B. 
Stability of the NLC 
Particle size, PDI, and drug content were analyzed to evaluate the physical and chemical stability 
of the formulation. Alteration in particle size and PDI are significant indicators of physical stability 
(244). Some AmB (1-2 %) stays unentrapped and settles out within 24 h. The optimized 
formulation was stable for 1 months at both 4 oC and 25 oC (Figure 16), ascribed to electrostatic 
and stearic stabilization. The surface charge (-50 to -55 mV) on PEG-NLC-AmB causes 
electrostatic repulsion between particle, thereby preventing aggregation of nanoparticles. In 
addition to the surface charge, bulky corona of the PEG on the surface of the nanoparticles causes 
















Figure 16: Evaluate PDI (a), entrapment efficiency (b), and particle size (c) for stability at 
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The autoclaved PEG-NLC-AmB were stable with insignificant differences in particle size and 
entrapment efficiency. However, a significant reduction (p < 0.05) in PDI was observed post 
autoclave (Figure 16). However, this could be due fluidity of NLC at elevated temperature, leading 
to collision and breaking of larger nanoparticles, causing narrow PDI. It is known that autoclaving 
can further enhance the stability of the nanoparticles, due to the formation of lipid bilayer around 
the particles (245-248). 
In vitro fungicidal activity 
A microdilution experiment was performed in wild type (WT) Candida albicans (ATCC90028), 
AmB resistant Candida albicans (ATCC 200955) and Aspergillus fumigatus (ATCC 204305) as 
per Clinical & Laboratory Standards Institute (CLSI) protocols 41-43. PEG-NLC-AmB, NLC-
AmB, AmB pure compound (AmB) and commercially available AmB formulations Fungizone 
and AmBisome were tested. Recovery assay was performed for fungicidal activity at both day 1 
and day 10 post preparation. At day 1 in Candida, PEG-NLC-AmB showed the strongest 
antifungal activity among AmB, Fungizone and AmBisome (Fig. 17 A & Table 14). The recovery 
assay also established lowest minimum fungicidal concentration (MFC) value for PEG-NLC-AmB 
i.e. 0.16 μg/mL. Against Aspergillus, PEG-NLC-AmB showed lower MIC value (1.25 μg/ml) 
compared to AmB (2.5 μg/ml) and was comparable to AmBisome (1.25 μg/ml). MIC with 
Fungizone was 0.62 μg/ml (Table 14). 
At day 10 post formulation, autoclaved PEG-NLC-AmB (PA-PEG-NLC-AmB) was also included 




Figure 17: Antifungal activity of AmB formulations. Left panel shows Java Tree visualization 
of microdilution assay data. Right panel shows cell recovery on drug-free agar plates. Each 
formulation was tested at 5.0-0.01µg/ml with 2-fold dilutions. Color bar represents relative 
growth.  A. Antifungal activity on Day 1 post AmB formulation in WT Candida.  B. & C. 
Antifungal activity on Day 10 post AmB formulation in WT and AmB resistant Candida 
strains, respectively. Each experiment was performed in triplicates. Here, PEG-NLC-AmB 
represent PEG2K-NLC-AmB.  
  
5 2.5 1.25 0.62 0.31 0.16 0.08 0.04 0.02 0.01
5 2.5 1.25 0.62 0.31 0.16 0.08 0.04 0.02 0.01
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Table 14: Summary of Antifungal profile of formulations.   
  


























PEG2K-NLC-AMB 0.08/0.31 0.16/0.31 1.25 1.25 1.25 
PEG2K-NLC NA/NA NA/NA NA NA NA 
AmB-NLC 0.16/0.62 0.16/2.5 NA NA 1.25 
NLC NA/NA NA/NA NA NA NA 
PA-PEG2K-NLC-AmB ND/0.16 ND/0.31 1.25 2.5 ND 
AmB 0.62/0.62 1.25/1.25 2.5 2.5 2.5 
Fungizone® 0.31/0.62 0.31/0.63 1.25 1.25 0.62 
AmBisome® 0.62/1.25 0.62/1.25 NA NA 1.25 
 
 
*ND - Not Done, NA - Not Achieved  
In vitro cytotoxicity evaluation 
The placebo (no AmB) formulations PEGNLC and NLC alone were tested for cytotoxicity towards 
the retinal pigmented epithelial cells (ATCC ARPE-19) in a concentration range of 0.03% - 1%. 
PEGNLC and NLC did not show any toxicity up to a highest concentration of 1%. The drug 
formulations PEG-NLC-AmB, NLC-AmB, AmB, PA-PEG-NLC-AmB, Fungizone and 
AmBisome were tested in the concentration range of 0.95 – 30 μg/mL. They were not cytotoxic to 
ARPE-19 cells up to a highest concentration of 30 μg/mL, indicating a high therapeutic index. The 
control drug benzalkonium chloride was toxic with an IC50 of 3.9 μg/mL. 
Amphotericin B loaded SLNs have been evaluated by several research groups. Patel and Patravale 
prepared Amphotericin B loaded SLNs (amphotericin B load: 12.5 – 37.5 % w/w of lipid) for oral 
bioavailability evaluation (249-251); Butani, Yewale and Misra tested the utility of Amphotericin 
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B loaded SLNs (amphotericin B load: 7.4 – 11.4 % w/w of lipid) for topical application (252). The 
formulations demonstrated better permeability compared to Amphotericin B dispersion, 2-fold 
greater in vitro activity against  Trichophyton rubrum fungal species and the freeze dried 
formulations demonstrated 3M stability (250); Chaudhari, Desai, Patel and Patravale prepared 
Amphotericin B SLNs (amphotericin B load: 12.5 – 37.5 % w/w of lipid)  that had lower toxicity 
but had a higher MIC which was explained to be because of sustained release of Amphotericin B 
from the SLNs  (250-253); Garse, Jagtap and Kadam prepared Bifonazole loaded SLNs which 
were loaded in gels for topical application (254). 
Tripathi et al. (255) prepared NLCs of amphotericin B (amphotericin B load 0.01 % w/v of total 
formulation i.e. colloidal dispersion; 9 % w/w of lipid content) to increase therapeutic efficacy and 
reduce toxicity. The authors suggested that it would be preferable to deliver amphotericin B 
through NLCs. However, these formulations were very different from the present invention. 
Firstly, the formulations used organic solvents. Secondly the NLCs were not PEGylated. 
Importantly, the authors did not present any data on the stability of the NLCs in a colloidal 
dispersion state or autoclavability. Most importantly, the importance of the molecular weight of 
the PEG on the physical stability of the NLCs has not been identified, which makes this report 
unique. Fu et al. (256) prepared AmB loaded NLCs that had been surface modified with chitosan 
and evaluated these particles for ocular delivery. However, the formulations were not PEGylated 
nanoparticles. The authors did not study stability of the amphotericin B and also fails to mention 
amphotericin B load.  
In another study, DSPE-PEG 2000 was used to prepare PEGylated lipid nanoparticles (0.7 % w/v 
amphotericin B of total formulation). Although the authors call these PEGylated lipid 
nanoparticles the formulations appear to be liposomes, which is distinctly different from the NLCs 
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described in the present disclosure. Moreover, this article does not disclose the critical importance 
of the PEG molecular weight on the drug loading, physical and chemical stability of the 
nanoparticles in a colloidal dispersion or the effect of autoclaving on the physicochemical 
characteristics of the amphotericin B loaded lipid nanoparticles (257). 
In vitro and In vivo evaluation 
AmB was not detected in the receptor chamber in an in vitro transcorneal study, for both 
AmBisome® and PEG-NLC-AmB. Therefore, the drug is delivered to the cornea at same rate from 
both the AmB formulations. Due to slow flux across cornea, AmB was not detected in the receptor 
media in 3 hours (258). The study cannot be extended beyond 3 hours as the corneal integrity 
would be lost.  
Damaged epithelium causes the uncontrolled amount of water to reach stroma, causing swelling 
of proteoglycans  (25, 259). The percent corneal hydration in the range of 76 to 83 % indicates that 
corneal integrity was intact (260). In the current study, percent hydration (78.8 ± 2.51 % w/w) was 
in the above-mentioned range, therefore, we can conclude that the cornea did not lose integrity 
upon contact with an AmB loaded formulation for 3 hours. PEG-NLC-AmB were studied in vivo 
in Albino New Zealand rabbits. The dosing frequency (50 µL every 60 min.) simulated the 
frequency in a severe ocular fungal infection. Amphotericin B was detected in all the tissues for 
PEG-NLC-AmB and AmBisome® (Figure 18). This is the first study that evaluates and compares 
in vivo ocular biodistribution of PEG-NLC-AmB with marketed preparation. A few reports have 
formulated amphotericin B loaded formulation for ocular drug delivery. The studies have reported 
in vitro antifungal activity of the formulations. However, none of the reports talk about the 
formulations efficacy in delivering drug to various ocular tissues, neither in vitro nor in vivo. The 
studies were performed on healthy eye; however, an infected eye has damaged epithelium and 
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therefore, amphotericin B permeation would be much higher. It has been observed that 
amphotericin B marketed preparations are able to cure upon repeated administration. The major 
disadvantage of marketed preparations is that once they are reconstituted, exceptional care has to 
be taken in order to prevent any precipitation and bacterial contamination. According to the label 
of the marketed preparations, they must be used within 24 hours post-reconstitution and stored at 




Figure 18: Concentration (ug/g) of amphotericin B in various ocular tissues (aqueous humor, 
cornea, iris-ciliary body, sclera, and vitreous humor (+/- 1 Standard Error). The 
concentration for Marketed preparation and PEGylated NLC for all the tissues were not 
statistically significant (p<0.05). 
Cornea ICB AH VH Sclera
AmBisome 0.05 0.09 0.01 0.02 0.063





























The quality-based design approach was used to optimize PEG-NLC-AmB. The optimized 
PEGylated NLC with small particle size, narrow PDI were formulated, which were stable for the 
at least one-month duration. This study is the first report—to author’s knowledge—comparing the 
ocular distribution of PEG-NLC-AmB and AmBisome® (marketed amphotericin B liposome). 
Additionally, the unique effect of mPEG-2000-DSPE to enhance amphotericin B loading and 
prevent drug leaching has not been reported before. Further investigations are needed to 
understand the mechanism by which mPEG-2000-DSPE has effect on amphotericin B loading 
efficiency. A critical finding of these report is that the innovative PEG2K-NLC-AmB had 
significantly enhanced anti-fgunal activity against wildtype and resistant species in comparison to 
the marketed preparation. The study also reports PEG-NLC-AmB whose ocular bio-distribution is 
statistically insignificant in comparison to the marketed liposomal preparation. The PEGylated 
NLC were prepared using a solvent-free processing and high-pressure homogenizer (ease of scale-
up), making it potential economic alternative for AmBisome® for ocular drug delivery of 
amphotericin B. In addition, the PEGylated NLC also form the base, which on further surface 
engineering, potentially could form NLC with superior in vivo characteristics in comparison with 
marketed liposome for ocular drug delivery. However, the comparison of amphotericin B NLC 








Strategies to Prolong Amphotericin B’s Precorneal Residence—Pegylated 
Lipid Nanoparticles Entrapped in the Ion-Sensitive Hydrogel and 
Chitosan-Coated Pegylated Lipid Nanoparticles 
Introduction 
In previous chapter, we reported formulation, optimization, and stabilization of 
amphotericin B loaded-PEGylated (2K) nanostructured lipid carriers (PEG2K-NLC-AmB). We 
observed that PEGylation enhanced stability of the amphotericin B in the nanoparticles and 
reduced leaching of drug over time. PEGylated nanostructured lipid carriers were physically and 
chemically stable for over the month and retained its stability upon autoclaving. From the 
biodistribution studies we observed that amphotericin B from lipid nanoparticles permeated 
through the scleral pathway (AmBisome® and nanostructured lipid carriers). Form literature it 
was known that amphotericin B deoxy cholate (Fungizone®) led to permeation of amphotericin B 
though corneal pathway as sodium deoxycholate is known to cause opening of tight junctions. In 
addition, it is known that sodium deoxy cholate, a major constituent of Fungizone® (marketed 
amphotericin B product), a permeation enhancer, can cause adverse effects on cornea upon 
repeated exposure (211). These formulations are administered primarily as eye drops in case of 
severe fungal infections and known to be short-lived in precorneal region due to precorneal
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 drainage. In case when product is ineffective in curing an ocular fungal disease, 
ophthalmologist choose to administer formulation either as intravitreal injection or via parenteral 
route, which are known to cause poor patient compliance. Systemic administration of amphotericin 
B needs close monitoring to prevent systemic adverse effects. This creates a need for developing 
formulation that can be administered as topical drops and also have prolonged precorneal 
residence.  
No enhancement in permeability was observed from in vivo biodistribution studies for 
amphotericin B loaded PEGylated nanostructured lipid carrier in comparison to AmBisome®, 
which can be attributed to slow permeation of amphotericin B and faster precorneal drainage.  In 
order to prolong precorneal residence time, we employed and compared two strategies: 1. Chitosan 
coated PEGylated nanostructured lipid carriers, 2. Entrapment of PEGylated nanostructured lipid 
carriers in in situ gelling system. Therefore, the primary aim was to study the effect of transforming 
the surface of PEG-NLC-AmB mucoadhesive (by using chitosan) and entrapping PEG-NLC-AmB 
in in situ gelling systems on precorneal residence and in vivo biodistribution. In earlier chapter we 
observed that PEG-NLC-AmB were stable upon autoclaving. These formulations will be dosed 
multiple times due to chronic nature of the fungal infection and hence, require certain preservative 
to keep formulation sterile. Marketed preparation is incompatible with preservative due to charge-
charge interaction; therefore, our secondary aim was to study effect of preservative (Benzalkoium 
chloride) on the stability of the formulations. 
Materials and methods 
 Materials 
AmB was purchased from Cayman Chemicals Pvt. Ltd. (Michigan, US). PrecirolTM ATO 5 was a 




2000-DSPE) was obtained from Lipoid GmbH (Germany). mPEG-DSPE were obtained from 
Creative PEGWorks® (Chapel Hill, NC, USA). Surfactants, Benzalkonium chloride, castor oil, 
xanthan gum, gellan gum, and analytical grade solvents were procured from Fisher scientific 
(Massachusetts, US). Chitosan chloride (Protasan®) was obtained from FMC biochemicals 
(Norway). Whole eyes of male albino New Zealand rabbits for the transcorneal study were 
procured from Pel-Freez® Biologicals (Rogers, AR, USA). 
Fabrication of chitosan coated- and gel entrapped PEGylated and Non-PEGylated NLC  
AmB-NLC were prepared using the formula in Table 15 and following procedure described in 
CHAPTER II. To prepare chitosan coated PEG-NLC-AmB system (Chi-PEG2K-NLC-AmB), 
chitosan was added to PEG-NLC-AmB and stirred for 10 mins at 2000 rpm (Table 13). 
Concentration of chitosan was selected as per earlier report from Dr. Majumdar’s lab (261). 
To prepare PEG-NLC-AmB entrapped in in situ gelling systems (PEG-NLC-AmB-Gel), small 
modification in the procedure was required. The lipid phase along with AmB was heated to 75oC 
and a coarse emulsion was formed by dropwise addition of the aqueous phase to the lipid phase 
under magnetic stirring at 2000 rpm. Further, the ULTRA-TURRAX® T 25(IKA works INC., NC, 
USA) was used to homogenize the coarse emulsion into a fine emulsion at 16000 rpm 
(temperature: 60o C). This fine emulsion was homogenized (temperature: 50o C) at 1500 bars for 
5-15 mins in high-pressure homogenization (HPH) (Emulsiflex C5-Avestin, Canada). To this 
emulsion gellan gum and xanthan gum were added and homogenized with ULTRATURRAXTM 
for 2 mins at 16000 rpm. Effect of concentration of gellan gum (0.1-0.5 % w/v) and xanthan gum 
(0.1-0.3% w/v) on physicochemical characteristics—particle size, polydispersity index (PDI), zeta 
potential (ZP), gelling time, firmness, viscosity, entrapment efficiency, drug loading, and total 
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drug content—were studied to obtain an optimized formulation (Table 16).  
 
 














ATO 5 3 3 3 3 
Castor Oil 1.5 2 2 2 
mPEG(2K)-
DSPE. Na salt  0 0.75 0.75 0.75 
Cremophor® 
EL 1.5 0 0 0 
Amphotericin 
B 0.1 0.3 0.3 0.3 
Aqueous phase 
Tween 80 0.8 0.8 0.8 0.8 
Poloxamer 
188 0.3 0.3 0.3 0.3 
Glycerin 2.5 2.5 2.5 2.5 
Water QS QS QS QS 
Xanthan gum NA NA NA 0.1-0.3 




are formed) NA NA 0.1 NA 
 
Table 16: Formulation run with variable xanthan and gellan gum to select optimized in situ 
gelling agent.  




B: Gellan Gum 
mg/10 mL 
 mg mg 
1 10 50 
2 20 30 
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3 10 10 
4 30 10 
5 10 30 
6 20 50 
7 30 30 
8 30 50 
9 20 10 
 
Fabrication of Formulation with Benzalkonium chloride (BAK; preservative) 
To the amphotericin B formulations (AmBisome®, Fungizone®, PEG-NLC-AmB, Chi-PEG-
NLC-AmB, PEG-NLC-AmB-Gel) 0.05% (w/v) of weighed BAK is added and stirred for 5 mins 
at 2000 rpm to ensure homogenous mixing of preservative. Changes in particle size and PDI of all 
formulations were observed for 7 days.  
Bioanalytical Method for quantification of AmB 
For quantification of AmB in the in vivo samples, a Waters Xevo TQ-S triple quadrupole tandem 
mass spectrometer with an electrospray ionization source, equipped with the ACQUITY UPLC® 
I-Class System was used (Waters Corporation, Milford, MA, USA). Data acquisition was 
performed with Waters Xevo TQ-S quantitative analysis TargetLynx® software and data 
processing was executed with MassLynx® mass spectrometry software. Separation operations 
were accomplished using a C18 column (Acquity UPLC® BEH C18 100 mm×2.1 m, 1.7μm 
particle size). The mobile phase consisted of water (A), and acetonitrile (B) both containing 0.1 % 
formic acid at a flow rate of 1.0 mL/min with a gradient elution as follows: 0 min, 98 % A/2 % B 
held for 0.2 minutes and in next 2.3 min to 100% B. Each run was followed by a 1-minute wash 
with 100 % B and an equilibration period of 2 minutes with 98 % A/2 % B. The column and sample 
temperature were maintained at 50ºC and 10C, respectively. The effluent from the LC column 
was directed into the ESI probe. Mass spectrometer conditions were optimized to obtain maximal 
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sensitivity. The following conditions were used for the electrospray ionization (ESI) source: source 
temperature 150°C, desolvation temperature 600°C, capillary voltage 3.0 kV, cone voltage 40 V, 
nebulizer pressure, 7 bar and nebulizer gas 1100 L·h−1 N2. Argon was used as the collision gas. 
The collision energies were optimized and ranged from 10 to 15 eV for individual analytes. 
Instrument control and data processing were performed by using MassLynx® software (version 
4.1, Waters, Milford, MA, USA). Mass spectra were acquired in positive mode and multiple 
reaction monitoring (MRM) mode. The multiple reaction monitoring (MRM) mode was applied 
to monitor the transitions of quantifier ion to qualifier ions (the precursor to fragment ions 
transitions) of m/z 924.4  m/z 107.5, 743.2, 761.4 for AmB and m/z 666.2  m/z 467.2, 485.2, 
503.2 for natamycin. Natamycin was used as the internal standard. Confirmation of compounds 
was achieved through three fragment ions. 
AmB was quantified - by inverse prediction of concentration from the peak area obtained for LC-
MS/MS—using a calibration curve (coefficient of determination r2 ≥ 0.98) determined for ocular 
tissues, such as the cornea, Iris-Ciliary Bodies, Aqueous Humor, Vitreous Humor, and Sclera. The 
process and extraction efficiency were greater than 90% for all the tissues. 
 Physicochemical characterization of NLC 
Assay, drug loading, and entrapment efficiency 
The drug was extracted from NLC with a 50:50 solvent mixture of DMSO and methanol. For the 
total drug content, the formulation (10 µL) was diluted 100 times with the solvent mixture (990 
µL), stirred vigorously, and centrifuged at 13000 rpm. The drug in the supernatant was quantified 
using HPLC. Entrapment efficiency of the drug was calculated by determining the free 
unentrapped drug. The formulation was filtered through the Amicon® filters (pore size of 100,000 
Daltons) at 5000 rpm. The drug in the filtrate was quantified with HPLC. Percent entrapped drug 
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  (3.2) 
Where, Wt = Total AmB content in the formulation  
 Wf = AmB in the aqueous phase 
 Wl = Total weight of the nanoparticles. 
Particle size, PDI, and zeta potential 
Dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, USA) was used to measure 
mean hydrodynamic particle size (z-average), PDI, and zeta potential. The formulations were 
diluted 100 times prior to measurements. All the measurements were made at 25oC.  
Characterization of Gel 
Gelling time: Nine scintillation vials were filled with simulated tear fluid (10 mL; pH 7.4) to which 
500 µL of nine amphotericin B loaded PEGylated NLC entrapped in gel formulations (Table 16) 
were added, respectively. The gel depot formation time and the time till drop remained intact or 
drop retained its shape was recorded. The time required for the gel depot to form was determined.  
Rheology: Bohlin Visco 88 viscometer (Malvern analytical, UK) was used for rheological 
characterizations. It is a cup and bob type viscometer. C14 probe was used to determine rheological 
behavior and viscosity of the formulations. Six hundred microliters of the sample at room 
temperature was used for the rheology analyses, which was carried out in the “up & down” ramp 
mode, at pre-defined multiple shear rates (ranging from 66.5-506.5 1/s). The rheology data was 
analyzed using Bohlin Software (Version 6.32.1.2).   
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Texture analyses (firmness and work of adhesion): Texture analyzer TZ.XT2i (Texture 
Technologies Corp., USA) was used to analyze in situ gelling systems. To analyze firmness and 
adhesion, a 1” diameter (TA3) acrylic (cylindrical) probe with a soft matter kit (TA-275) was 
used(262).  The sample of in situ gelling system was added in the soft matter cup and parameters 
used for the analyzes are listed in Table 17.   
Table 17: Parameters for texture analyses of gels. 
Parameter Set value 
Test mode Compression 
Pre-test speed 0.5 mm/sec 
Test speed 0.5 mm/sec 
Post-test speed 0.5 mm/sec 
Target mode Distance 
Distance 1.0 mm 
Trigger type Auto (Force) 
Trigger force 2.0 g 
Temperature Room temperature 
 
The probe (controlled by software) is lowered till contact with gel is sensed. Upon contact, 
probe travels 1 mm distance at speed of 0.5 mm/s and retracts. The force required by the probe to 
travel 1 mm in to the gel is recorded and processed to give firmness and work of adhesion.  
In vitro antifungal activity 
For Antifungal susceptibility assays AmB formulations were tested against Candida albicans 
(SC5314, ATCC MYA-2876) and AmB resistant Candida albicans (ATCC 200955) following 
CLSI guidelines. Seven days old, stored at 40C after preparation, nanoparticle formulations were 
serially diluted using RPMI 1640, pH 7.0 medium. After dilution samples were transferred in to 
96 well assay plates (10 μL) in duplicate.  Inocula was prepared by suspending growth from agar 
in 0.9% saline and diluted in RPMI 1640 (pH7.0, MOPS) medium after comparison to the 0.5 
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McFarland standard to have a final inoculum of 1.0 x 104 CFU/ml in 190 μL of the medium.  The 
assay plates were measured at the OD530 wavelengths prior to and after incubation at 35°C for 48h.  
MICs, defined as the lowest test concentration that allows no visual growth, were calculated for 
all formulations. To determine MFCs, 4 μL aliquots of cells from each well of MIC plate was 
spotted on drug-free SD agar plates and was incubated for 24-48h.  MFC is defined as the lowest 
test concentration that allows no detectable growth on drug free agar plate. Each experiment were 
performed in triplicates. 
In vivo precorneal kinetics 
In vivo pre-corneal tear kinetics of the various amphotericin B formulations (PEG2K-NLC-AmB, 
Chitosan PEG2K-NLC-AmB, PEG2K-NLC-AmB Gel, AmBisome®, Fungizone) was determined 
in male New Zealand White Albino Rabbits, weighing 2-2.5 kg, which were procured from Charles 
River Labs. All the animal studies conformed to the tenets of the Association for Research in 
Vision and Ophthalmology statement on the use of animals in ophthalmic vision and research and 
the University of Mississippi Institutional Animal Care and Use Committee approved protocols. 
The rabbits were dosed (50 µL) with amphotericin B formulations topically. Therefore, the amount 
of amphotericin B dose received by the rabbits would be 0.15 mg form all the formulations tested. 
The tear samples were collected by gentle touching a pre-weighed piece of filter paper at the 
corneal surface at every time point (t = 0, 0.25, 0.5, 1, 2, 4, and 6 hours). The wet weight of the 
filter paper was then recorded and the difference in their dry and wet weights was used in the 
determination of the amount of tear fluid that was collected, which was used in the estimation of 
amphotericin B from the tear biosamples. The extraction of amphotericin B from the tear 
biosamples collected on filter papers was performed by adding six hundred microliters of 50:50 
mixture of ice-cold methanol and dimethyl sulfoxide, mixing thoroughly using a vortex genie 
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mixer, and then centrifuging at 13,000 rpm for 15 minutes in a table-top centrifuge. The 
supernatant was then collected and analyzed for amphotericin B using a validated HPLC 
quantification method that has been outlined above (0073). The data was then analyzed using 
PKNCA package using R to determine various PK parameters (263). Once the study was 
completed, Balanced Salt Solution (BSS) was used for washing the test eyes of the rabbits during 
the wash-out period. 
In vivo ocular bio-distribution studies 
In vivo, ocular biodistribution of AmB was studied in 24 male New Zealand albino rabbits 
(weighing around 2 - 2.5 kg), procured from Harlan Labs (Indianapolis, IN, USA). All animal 
studies conformed to the tenets of the Association for Research in Vision and Ophthalmology 
statement on the use of animals in ophthalmic vision and research and the University of Mississippi 
Institutional Animal Care and Use Committee approved protocols. Rabbits were anesthetized 
using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg), injected intramuscularly.  
The AmB formulations: PEG2K-NLC-AmB, chitosan PEG2K-NLC-AmB, PEG2K-NLC-AmB 
and AmBisome® (marketed AmB liposomes), were evaluated in vivo in conscious rabbits (n=4). 
Four doses of each formulation were administered (50 μL each) 120 min apart. Two-hour post-
instillation of the final dose, the rabbits were euthanized with an overdose of pentobarbital injected 
through a marginal ear vein. Two groups of 4 rabbits each were dosed thrice with chitosan PEG2K-
NLC-AmB and PEG2K-NLC-AmB gel (50 μL each) 180 min apart. The eyes were washed 
thoroughly with ice-cold phosphate-buffered saline and enucleated. All the ocular tissues were 
separated and homogenized; The drug was extracted from the tissues using an ice-cold solvent 
mixture (9:1- methanol: DMSO) and analyzed for AmB content according to the procedure 
described in Section 2.6. 
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Stability of the NLC 
Optimized PEG-NLC-AmB were autoclaved (AMSCO® Scientific Model SI-120) in the 
scintillation vials, at 121°C for 15 min under 15 psi pressure. The autoclaved samples were 
gradually cooled to room temperature a nd formulations were evaluated for its physicochemical 
characteristics (Section 2.7). The non-sterile formulations (stored at 4 and 25oC) were controls for 
the sterile formulations.  The optimized PEGylated NLC was evaluated for its stability upon 
storage for a duration of 8 weeks at 25°C/75% RH and 4°C. The physicochemical evaluations were 
performed as mentioned earlier in this chapter.  
Statistical analysis 
Analysis of variance (ANOVA) was used to analyze data from the in vivo biodistribution studies. 
At p<0.05, the differences in data were considered statistically significant. In case of comparison 
of two groups, two-way student ‘t-test’ was utilized.  
Result and Discussions 
The objective of this study was to modify PEG2K-NLC-AmB to retain them in precorneal region 
for extended period. This can be achieved by adopting strategies like mucoadhesion, increasing 
viscosity of the formulation, formulating films, and similar dosage forms. Here, in these regards, 
we have used chitosan surface modification that would make nanoparticles mucoadhesive and 
compared it with nanoparticles entrapped in in situ gelling system. These ingredients used are from 
natural origin and proved to be safe in concentrations used.  
Fabrication of Chitosan coated PEG2K-NLC-AmB (Chi-PEG2K-NLC-AmB) 
Chitosan chloride salt was dissolved in the aqueous phase and allowed to coat the surface by 
electrostatic attraction (261). Concentration of chitosan (0.3 %w/v) was obtained from published 
reports from Dr. Majumdar’s lab studying effect of chitosan concentration on coating of the 
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nanoparticles. Physicochemical characterizations of chitosan coated vs uncoated PEG2K-NLC-
AmB is summarized in Table 18. Post coating with chitosan, particle size of nanoparticles was 
seen to increase from 302 ± 78 to 375 ± 2.91 nm. This increase in particle size was expected as it 
signs coating of chitosan on the surface of nanoparticles, which was confirmed by zeta potential. 
Zeta potential post coating with chitosan increased from -60 to +25 mV. Mucous on the surface of 
the eye is negatively charged and hence, positively charged nanoparticles would bind to mucous 
by electrostatic attraction and thereby, reducing precorneal drainage of the nanoparticles, and 
providing prolonged exposure. Another interesting observation was that entrapment efficiency 
increased post-coating from 93.7 ± 7 to 102 ± 0.15 %. This was unexpected, however, a recent 
report suggested that chitosan coating leads to increase entrapment efficiency of amphotericin B 
in the nanostructured lipid carriers (264). However, the authors were not able to load beyond 0.1 
% (w/v), which signifies that PEGylation had greater effect on enhancing entrapment efficiency 
than chitosan.  
Table 18: Physicochemical characterization of PEG2K-NLC-AmB, Chi-PEG2K-NLC-





Particle Size 316 ± 8.77 375 ± 2.91 190 ± 6.2 
Polydispersity Index 0.35 ± 0.01 0.35 ± 0.009 0.25 ± 0.01 
Percent Entrapment 
Efficiency 
93.7 ± 7 102 ± 0.15 99.15 ± 1.2 
Zeta Potential +25 mV -60 mV -55 mV 
 
Fabrication of PEG2K-NLC-AmB entrapped in in situ gels (PEG2K-NLC-AmB-Gel) 
Increasing viscosity of the eye drops is a widely used and most effective strategy to prolong 
residence time of the formulation in the cul-de-sac. However, due to high viscosity it leads to poor 
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patient compliance and inaccurate dosing. Therefore, to overcome these disadvantages, we used 
in situ gelling system that has solution viscosity unless it is triggered to form gel. Triggers (cations, 
temperature, pH) can depend on polymer/s used. We used a combination of two natural 
polylactide, One of them being gellan gum—known to form soft-gels (low-viscosity gels) when 
in contact with cations (present abundantly in tears), and Other polysaccharide used was xanthan 
gum which added firmness and viscosity to the gel formed, preventing disruption of gel structure 
and precorneal loss on blinking. To form PEG2K-NLC-AmB-Gel, procedure was slightly 
modified. This was done as incorporation of these gums after forming nanoparticles was difficult 
without using high-shear ULTRATURRAXTM. Concentrations of xanthan gum and gellan gum 
were varied (Table 16) to form different formulations and were tested to achieve desired 
formulations. 
From the gelling time and depot collapse time it was evident that 50 mg gellan gum was necessary 
to instantaneously form gel depot and maintain its structure. For all the formulations with gellan 
gum concentration at 10 mg, depot was not formed on contact with simulated tear fluid (STF). For 
formulations with gellan gum concentration 20 mg, the depot was formed instantaneously, 
however, the depot structure was lost to form threads, which existed for 2-4 hours. The results are 
summarized in Table 19. Therefore, further tests were performed on formulation 1,6, and 8 to 
select optimum formulation.  
Table 19: Effect of concentration of xanthan gum and gellan gum on gelling time and depot 
collapse time.  










  mg/10 mL Mg/10 mL     
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1 10 50 (+) >12 hours 
2 20 30 + <2 hours 
3 10 10 (-) NA 
4 30 10 (-) NA 
5 10 30 + <2 hours 
6 20 50 (+) >12 hours 
7 30 30 + <4 hours 
8 30 50 (+) >24 hours 
9 20 10 (-) NA 
     (-): does not instantaneously form a gel depot by coming in contact with STF; +: Forms 
a gel depot, however, depot structure is lost in <5 mins (broken into threads); (+): forms a gel depot 
spontaneously and retains its structure.  
 
Texture analyzer was used to characterize firmness and work of adhesion for run 1,6, and 8 (Table 
20). Formulation 8 had higher firmness and work of adhesion. However, difference was not huge 
to select a formulation. The formulations were furthered compared on basis of viscosity (Table 
20). The pre-gelling viscosity for formulation is preferred to be low as it would provide ease of 
administration and accurate dosing. Therefore, formulation 1 was selected for further in vivo 
evaluations. In addition, it was also observed that these formulations showed sheer-thinning and 
absence of thixotropy (Figure 19). Therefore, in vivo it is expected to lose viscosity upon blinking 
and form a thin layer over the cornea and retain viscosity when blinking stops. This would lead to 
increase in surface area of the cornea in contact with the formulation and also maintain some 




Figure 19: Viscosity vs shear rate plot. 
Table 20: Firmness, work of adhesion, and viscosity for run 1,6, and 8. 
Run 
Xanthan Gum 






(cPs) at 15 s-1 
Work of 
Adhesion (g.sec) 
1 10 50 5.01 502.77 22.57 
6 20 50 5.76 569.36 23.52 
8 30 50 6.89 776.55 25.55 
 
Physicochemical characterizations of PEG2K-NLC-AmB and selected PEG2K-NLC-AmB-Gel is 
summarized in Table 18. We see significant reduction in the particle size and PDI. This is due to 
two possible reasons; 1. Modified method had ULTRATURRAXTM at the end which led to further 
reduction I the particle size, 2. These gum increase viscosity of the external phase of the 
nanoparticles, thereby, stabilizing nanoparticles immediately by reducing free/Brownian 





















(102 ± 0.15).  
Compatibility with Benzalkonium Chloride 
A major drawback of the currently available amphotericin B formulations is that preservatives 
cannot be added to the formulations because of stability issues. The stability of various 
formulations prepared as per the invention against the marketed reconstituted solutions were 
tested. 
As seen in Table 7, addition of BAK to reconstituted AmBisome® or FungizoneTM led to the 
formation of aggregates (7-8-fold increase in particle size and PDI 7 days after addition of BAK-
0.05 % w/v). On the other hand, addition of BAK to the PEG2K-NLC-AmB formulation did not 
lead to any change in the physical characteristics of the formulation (particle size or PDI). The 
BAK added formulations did not show any decrease in antifungal activity against Candida on Day 
1; however, after 7 days a decrease in fungicidal activity was seen with the AmBisome® + BAK 
and Fungizone + BAK formulations. Besides a decrease in antifungal activity, increase in particle 
size could also lead to variations in ocular absorption and can also cause irritation and thus induce 
lacrimation and drug loss. Addition of Chitosan or in situ gelling agents improved the physical 
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In vitro fungicidal activity 
Microdilution experiments were performed in wild type (WT) Candida albicans SC5314 (ATCC 
MYA-2876) and in AmB resistant Candida albicans (ATCC 200955) as per Clinical & Laboratory 
Standards Institute (CLSI) protocols.  Recovery assay was performed for fungicidal activity at day 
7 post preparation (reconstituted formulations were stored at 4oC).  First NLC-AmB 
(unPEGylated), PEG-NLC-AmB, AmB pure compound (AmB) and commercially available AmB 
formulations, Fungizone and AmBisome, were tested.  The initial studies were performed in the 
Ca SC5314 strain in which, PEG-NLC-AmB showed the strongest antifungal activity among 
AmB, Fungizone and AmBisome (Fig. 20 A & Table 22). The recovery assay also established 
lowest minimum fungicidal concentration (MFC) value for PEG-NLC-AmB i.e. 0.16 µg/mL in 
comparison to AmB (1.25 µg/mL), Fungizone (0.31 µg/mL) and AmBisome 1.25 µg/mL). (Fig. 
20 A & Table 22). In AmB resistant Candida strain, PEG-NLC-AmB showed similar MIC/MFC 
values like Fungizone, but significantly better than AmB and AmBisome (Fig. 20 B & Table 22).  
Along with PEG-NLC-AmB formulations, chitosan coated PEG-NLC-AmB formulations as well 
as the PEG-NLC-AmB formulations in the in-situ gel system were also tested in both WT and 
AmB resistant Candida strains. In Ca SC5314, PEG-NLC-AmB formulations exhibited superior 
activity, even after 7 days post reconstitution, compared to the control or the marketed 
formulations. Chitosan coating or addition of the gel components did not affect the MIC or MFC. 
Moreover, the MIC and MFC of the PEG-NLC-AmB formulations were not affected by the 
preservative, BAC, whereas the efficacy of AmBisome and Fungizone were affected (Fig 20A & 
Table 22). Although, in AmB resistant Candida strain, coated PEG-NLC-AmB loses its activity 
in comparision with PEG-NLC-AmB alone and FunDex-BAC. The placebo formulations, PEG-





Figure 20: Antifungal activity of AmB formulations. Left panel shows Java Tree 
visualization of microdilution assay data. Right panel shows cell recovery on drug-free agar 
plates. Each formulation was tested at 10.0- 0.01μg/ml with 2-fold dilutions. Color bar 
represents relative growth. A. Antifungal activity on Day 7 post AmB formulation in WT 
Candida (SC5314). B.  Antifungal activity on Day 7 post AmB formulation in AmB resistant 




Table 22: Summary of Antifungal profile of formulations.   
  Candida albicans (SC5314) AmB-resistant Candida albicans    
  (ATCC MYA-2876) (ATCC 200955) 
Formulations MIC/MFC (µg/mL)  
PEG-NLC-AmB 0.16 / 0.16 1.25 / 1.25 
PEG-NLC-AmB-Gel 0.08 / 0.16 2.5 / 2.5 
PEG-NLC-AmB-Chi 0.16 / 0.16 5.0 / 10.0 
FunDex 0.31 / 0.31 1.25 / 1.25 
AmBisome 0.63 / 1.25 NA / NA 
PEG-NLC-AmB-BAC 0.08 / 0.16 2.5 / 2.5 
PEG-NLC-AmB-Chi-BAC 0.16 / 0.16 5.0 / 10.0 
FunDex-BAC 0.31 / 0.63 0.63 / 0.63 
AmBisome-BAC 0.63 / 0.63 10 / NA 
AmB 1.25 / 1.25 2.5 / 5.0 
PEG-NLC NA / NA NA / NA 
PEG-NLC-Gel NA / NA NA / NA 
PEG-NLC-Chi NA / NA NA / NA 
 
Precorneal tear kinetics 
Precorneal tear kinetics provides analysis of concentration available to absorb from precorneal tear 
fluid and cul-de-sac. We receive various parameters from precorneal kinetics: t1/2, Cmax, AUC, 
MRT. High t1/2 and MRT signifies higher precorneal residence. A formulation that has higher 
precorneal residence means amphotericin B can permeate for prolonged period of time. AUC 
provides concentration overall in contact with cornea during total time duration. Higher the AUC, 
higher concentration gradient across cornea and sclera and possible higher permeation. Precorneal 
tear concentrations were determined (Table 24) and plotted against time in Figure 21. Further, 
non-compartmental analysis on tear fluid kinetics was applied and summarized in Table 23. From 
the precorneal tear fluid kinetics (t1/2) it was evident that PEG2K-NLC-AmB-Gel had ~4-fold 
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higher precorneal residence in comparison to AmBisome® (marketed Amphotericin B liposome) 
and ~17 fold higher than FungizoneTM. It is also evident that nanoparticles enhance precorneal 
residence in comparison to solution (FungizoneTM v/s rest). AUC for amphotericin B formulations 
from highest to lowest are: PEG2K-NLC-AmB-Gel>Chi-PEG2K-NLC-AmB> PEG2K-NLC-
AmB>AmBisome>Fungizone. Therefore, we can conclude that nanoparticles entrapped gel 
provided highest great amphotericin B concentration in precorneal region for prolonged duration. 
Cmax was consistent with all formulation except in situ gelling system, which had 1.5 higher Cmax, 
which signifies lower initial loss upon blinking post administration of dose. Upon administration 
of eye drops, we see loss due to overflowing of cul-de-sac. This is not seen in case of nanoparticles 
entrapped in in situ gelling system as the eye drop is immediately converted to gel (high viscosity), 
and form depot in the cul-de-sac. Similar observation can be made by comparing concentration of 
these formulation at time 0 (Table 24).   
Table 23: Precorneal tear fluid kinetics. 
 
 
Overall, PEG2K-NLC-AmB-Gel had higher t1/2, MRT, Cmax, and AUC. Therefore, this 
formulation can help us reduce number of dosing required in a day by prolonging amphotericin B 
residence in precorneal region.  








t1/2 h 1.54 4.77 2.26 4.51 17.66 
Cmax/ C0 μg/μl 4.74 5.36 4.90 5.68 7.84 
AUC 0-t μg/μl*h 0.85 0.76 1.19 1.27 2.05 
AUC 0-
inf_obs 
μg/μl*h 0.88 0.81 1.24 1.46 2.75 
AUMC 0-
inf_obs 
μg/μl*h^2 0.38 0.84 0.94 3.16 22.96 
MRT 0-
inf_obs 
h 0.43 1.04 0.76 2.17 8.35 
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Table 24: Summary of concentration at various time point in tear fluid.  
Ti
me AmBisome Fungizone PEG-NLC 
Chitosan PEG-






























































































Figure 21: Precorneal amphotericin B tear concentration.  

























AmBisome Fungizone PEG-NLC Chitosan PEG-NLC PEG-NLC GEL
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This study was performed in total 24 New Zealand albino rabbits. They were divided in 6 groups 
with 4 rabbits in each group. Aim of this study was to study amphotericin B biodistribution post-
dosing of amphotericin B formulations. In previous study (Chapter II) we dosed animals every 
hour for 7 hours and sacrificed at 8th hour. This was planned to mimic closely to the regimen 
followed in a clinical set-up to treat a patient with fungal infection. We observed that amphotericin 
B concentration were statistically equivalent for all the formulations. Since, we modified 
formulation for better precorneal residence, to evaluate formulations, dosing was reduced to every 
2 hours for 6 hours and sacrifice at 8th hour. This would give idea if formulations survive despite 
of number of doses reduced to half. In 2 groups labelled as Chi-PEG2K-NLC-AmB 3and PEG2K-
NLC-AmB-Gel 3 (Figure 22) formulations were administered every 3 hours (total 3 doses) and 
animals were sacrificed at 9th hour. Results are summarized in Figure 22. Results suggest that 
PEG2K-NLC-AmB had lowest ocular biodistribution. This relates to its precorneal residence time, 
therefore, on reduced dosing formulation failed. In this study concentration in Sclera and Cornea 
are key as in state of infection cornea and scleral would have disrupted tight junctions and hence, 
permeability would be higher and concentration in ICB, AH, VH would not represent true value. 
Corneal concentration of chitosan coated PEGylated amphotericin B loaded nanostructured lipid 
carriers was high because of mucoadhesive nature of chitosan. Also, comparing ratio of 
concentration in sclera to cornea for formulations, it signifies that amphotericin B permeated 
through corneal pathway from chi-PEG2K-NLC-AmB, whereas, amphotericin B from 
AmBisome® and PEG2K-NLC-AmB permeate through scleral pathway.  
Concentration of amphotericin B from PEG2K-NLC-AmB-Gel were significantly higher and from 
precorneal kinetics it is proved that gel retains greater portion of its formulation in precorneal 
region. Therefore, number of doses for PEG2K-NLC-AmB-Gel can be reduced without 
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compromising effectiveness. More accurate idea on this can be obtained by testing these 
formulations on in vivo ocular fungal infection model in future.  
 
Figure 22: Ocular biodistribution of amphotericin B from amphotericin B loaded PEGylated 
(2K) NLC, chitosan coated PEGylated (2K) NLC, and PEGylated (2K) NLC entrapped in 
ion sensitive gels in comparison with AmBisome® (marketed preparation—freeze-dried 
liposome), in vivo in Albino New Zealand rabbits (Instillation volume 50 µL, Dose 150ug). 
The error bars represent standard error. Dosing regimen for PEG2K-NLC-AmB, chitosan 
PEG2K-NLC-AmB, and PEG2K-NLC-AmB Gel is 150 ug every 2 hours for 6 hours and 
sacrifice rabbits at 8th hour. Whereas, dosing regimen for chitosan PEG2K-NLC-AmB 3, 































Chitosan coated PEG2K-NLC-AmB and PEG2K-NLC-AmB entrapped in gel were formulated. It 
was observed that both formulations positively impacted stability. PEG2K-NLC-AmB-Gel 
demonstrated significantly prolonged precorneal residence of amphotericin B. Permeation of 
amphotericin B from the PEG2K-NLC-AmB-Gel, Chi-PEG2K-NLC-AmB, and PEG2K-NLC-
AmB formulations were significantly higher in compariosn to AmBisome® (marketed 
preparation).  PEG2K-NLC-AmB-Gel and Chi-PEG2K-NLC-AmB formulations were able to 
maintain statistically indifferent amphotericin B concentration even when number of doses were 
further reduced from 8 to 4 to 3. Where, highest amphotericin B formulation, amongst all studied 
formulation (except marketed AmBisome®), was in PEG2K-NLC-AmB-Gel. This signifies that 
PEG2K-NLC-AmB-Gel formulation prevented loss of amphotericin B while maintaining 
concentration of amphotericin B in precorneal region and various ocular tissues. A more complete 
idea on performance of these formulations can be gained by testing them on in vivo animal model.  
Therefore, from current studies we conclude that we were able to formulate an autoclavable high 
amphotericin B loaded stable formulation for ocular drug delivery with—its permeation at par 
with marketed preparation, prolonged precorneal residense, stablitiy in presence of preservative, 
multidose regimen compatible, significantly enhacned antifungal activity against wildtype and 
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